



ClearVue<sup>PV</sup>

Solar for every façade surface

# Annual Report 2025-26



## Contents

---

|                                                                         |    |
|-------------------------------------------------------------------------|----|
| Company Information                                                     | 3  |
| About ClearVue Technologies                                             | 4  |
| Strategic Pillars and Revenue Model                                     | 5  |
| Drivers for Growth                                                      | 6  |
| Product Overview                                                        | 7  |
| FY26 Highlights                                                         | 8  |
| Licence Partners & Strategic Partners                                   | 9  |
| Project Highlights                                                      | 10 |
| Chair's Letter to Shareholders                                          | 11 |
| CEO's Letter to Shareholders                                            | 12 |
| Directors' Report                                                       | 13 |
| Auditor's Independence Declaration                                      | 37 |
| Consolidated Statement of Profit or Loss and Other Comprehensive Income | 38 |
| Consolidated statement of Financial Position                            | 39 |
| Consolidated Statement of Changes in Equity                             | 40 |
| Consolidated Statement of Cash Flow                                     | 41 |
| Notes to the Consolidated Financial Statements                          | 42 |
| Consolidated Entity Disclosure Statement                                | 69 |
| Director's Declaration                                                  | 70 |
| Independent Auditor's Report                                            | 71 |
| ASX Additional Information                                              | 75 |

# Company Information

## CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES

ABN 45 071 397 487

### DIRECTORS

Ms Theresa Smits, Chair (appointed 8 July 2025, appointed to the Chair 12 August 2025)  
Mr Douglas Hunt, Managing Director and Chief Executive Officer (appointed 12 August 2025)  
Mr Michael Pixley, Non-Executive Director (appointed 8 July 2025)  
Mr Liang Ji, Non-Executive Director (appointed 12 November 2025)  
Mr Andrew Lau, Non-Executive Director (appointed 23 March 2026)  
Prof. Rebecca Yang, Non-Executive Director (appointed 16 July 2026)  
Mr Victor Rosenberg, Non-Executive Chairperson, Non-Executive Director (resigned as Chairperson 12 August 2025, resigned from the board 29 November 2025)  
Mr Jamie Lyford, Executive Director (resigned 8 July 2025)  
Mr Charles Mowrey, Non-Executive Director (resigned 14 July 2025)  
Mr Gerd Hoenicke, Non-Executive Director (resigned 4 August 2025)

### COMPANY SECRETARY

Mr Harry Miller

### REGISTERED OFFICE

Suite 9 / 567 Newcastle Street  
West Perth  
WA 6005

### PRINCIPAL BANKERS

National Australia Bank Limited Level 12, 100 St Georges Terrace Perth WA 6000

### AUDITORS

Grant Thornton Audit Pty Ltd  
Level 43, Central Park 152-158  
St Georges Terrace Perth WA 6000

### SOLICITORS

Steinepreis Paganin 16 Milligan Street Perth WA 6000

### SHARE REGISTRY

Automic Group  
Level 2, 267 St Georges Terrace Perth WA 6000

### STOCK EXCHANGE LISTING

Shares are listed on the Australian Securities Exchange  
(ASX code: CPV)

Shares are listed on the Over-the-Counter Exchange  
(OTCQB code: CVUEF)

# About ClearVue

---

ClearVue Technologies Ltd (“ClearVue” or the “Company”) is a global technology company, headquartered in Australia and specialising in the integration of advanced solar technology within building surfaces. ClearVue’s patented solar technology enhances the sustainability and energy efficiency of both new and existing buildings by generating energy from nearly all building façade surfaces.

ClearVue’s Solar Façade maximises on-site renewable solar energy generation for a sustainable building envelope. With ClearVue, a path toward net zero is within reach.

The Company has expanded on its offerings over the years to include Solar Vision Glass, Spandrel, Cladding, Balustrade, Skylights and Rooftop solutions. Today, this means making exterior building surfaces that were once inactive, now energy generators.

ClearVue addresses one of the most significant environmental challenges our world faces today: How to decarbonise the built environment.

Our ability to deliver practical, actionable, and quantifiable energy solutions for the built environment positions ClearVue to provide meaningful environmental, social and shareholder benefits over the medium to long term.

Supporting our technology portfolio, the Company holds an extensive array of global patents, designs, trademarks and trade secret protections. Additionally, ClearVue has undergone rigorous global testing to ensure safety, building and technical compliance with the relevant standards.

Since its listing on the Australian Stock Exchange (“ASX”) in May 2018, ClearVue’s geographic footprint now extends around the globe.

ClearVue is currently executing its global commercialisation plan. The Company is guided by a board with extensive industry experience, complemented by an equally experienced executive team, to drive significant outcomes for our customers and shareholders.



Enabling clean renewable energy generation from the whole building façade.

# Our Business Strategy & Revenue Model

1

ENGINEERED FOR  
MASS PRODUCIBILITY &  
MEET CONSTRUCTION  
STANDARDS

2

CONTINUOUS  
INNOVATION DRIVING  
DIFFERENTIATION &  
ADVANCEMENTS

3

GLOBAL  
COMMERCIALISATION  
GROWTH VIA  
PARTNERSHIPS

## REVENUE MODEL

DIRECT SALES TO GLOBAL PROJECTS



### COMPONENT SALES TO LICENCE PARTNERS

- Solar glazing (laminated front pane)
- Thermal Management Junction Box
- PowerBlock and PowerCorner
- Solar spandrel and cladding products as part of a system deployment approach



LICENCE RENEWAL FEES & ROYALTIES



The world is actively decarbonising but approximately 40% of the world's CO<sub>2</sub> emissions come from building and construction.



Global net zero goals aim to be achieved by 2050.



ClearVue's solar façade generates clean energy, reduces carbon footprint and supports a path towards net zero buildings.

# Drivers for Growth

GLOBAL TRENDS ARE SHAPING OUR WORLD AND FUELING CLEARVUE'S COMMERCIALISATION

1

## BUILDINGS ARE THE LARGEST UNSOLVED EMISSIONS PROBLEM



The construction sector is responsible for **37%** of global CO<sub>2</sub> emissions and almost **50%** of global material extraction.

Half of the buildings that will exist in 2050 are still to be built or renovated.<sup>1</sup>

Decarbonising the built environment cannot be achieved through equipment efficiency alone. Materials that generate energy while performing a structural function address operating and embodied carbon at the same time.

2

## FROM VOLUNTARY TO MANDATORY, ACROSS EVERY MAJOR MARKET



**100%** of new EU non-residential buildings must have solar from 31 December 2026.

**80%** of new Singapore developments must meet Super Low Energy standard from 2030.<sup>2</sup>

On-site generation is becoming a condition of building approval, not a design preference. EU, Singapore, Japan and a growing list of Southeast Asian markets now mandate solar or near-zero energy performance in new buildings. Where roof area cannot meet the obligation, the facade is the only surface left.

3

## URBAN GROWTH IS VERTICAL, SO THE AVAILABLE SURFACE IS GLASS



Global building floor area up by **1.7% per year** to reach **273 billion m<sup>2</sup>**, driven by construction in emerging economies.<sup>1</sup>

Green building certifications have nearly tripled over the past decade and global building energy intensity has fallen 8.5%.<sup>1</sup>

As cities densify, roof area per square metre of floor space keeps shrinking while glazed facade area grows. The facade is the only remaining surface at scale, and it is the surface ClearVue addresses.

4

## CAPITAL IS BACKING THE TRANSITION AT RECORD SCALE



**US\$2.2 trillion** of global energy investment is going to renewables, needs to double to around **US\$5.9 trillion** by 2030 to stay aligned with climate goals.<sup>3</sup>

For the first time clean energy is attracting close to twice the capital of fossil fuels, and the building efficiency funding gap is the largest single shortfall inside that picture.

<sup>1</sup> Source: UNEP / GlobalABC, Global Status Report for Buildings and Construction 2025–2026 (May 2026). <sup>2</sup> Sources: Directive (EU) 2024/1275, Article 10 / BCA Singapore, Green Building Masterplan / BCA, Sustainability & Super Low Energy / Tokyo Metropolitan Government, Solar Power Installation Requirement. <sup>3</sup> Sources: IEA, World Energy Investment 2026.

# Solar for Every Façade Surface



## ClearVuePV Vision Glass

ClearVue's Solar Vision Glass combines several patented, proprietary technologies to generate clean, renewable energy from clear building glazing surfaces.

## ClearVuePV Spandrel

ClearVue<sup>PV</sup> Spandrel replicates traditional black glass spandrel. The solution delivers excellent reliability, efficiency and performance for building sustainability.

## ClearVuePV Cladding

ClearVue offers a broad range of Cladding colours, patterns and textures. Our silicon-based cladding has the ability to generate significant power while offering a broad range of visual textures and colours to achieve architectural intent.

## ClearVuePV Skylight

ClearVue solar skylight solution maximises energy generation, designed for building canopies, atriums and a broad range of overhead glazing applications.

## ClearVuePV Balustrade

ClearVue's solar balustrade solution generates clean energy across building canopies, balcony railings and fencing.

## ClearVue-Helios Solar Solutions

ClearVue-Helios solar solutions are an exclusive, integrated rooftop metal-backed, tempered solar panel and framing system.

# FY26 Highlights

Our focus in FY26 was securing new projects globally. ClearVue secured three key projects across Europe, Australia and the Middle East. We continued to focus on product testing, certifications and advancements.



Credit: George Kalaitzides Architects | Rio Business Center, At: <https://www.gkarchitects.studio/project/rio-renovation>

## PROJECTS

- Rio Business Centre | Cyprus
- Canva Headquarters | Australia
- Qatar University Greenhouse | Qatar

## PRODUCT ADVANCEMENTS & CERTIFICATION MILESTONES

- ClearVue-Helios products certified to IEC61730 (2023) and IEC61215 (2021).
- Gen3 Vision Glass passes EN1279-5:2018.
- ClearVue Thermal Management Junction Box achieves IEC62790 certification.
- Vision Glass, Solar Cladding, Solar Spandrel, Solar Skylight and Solar Balustrade pass AS/NZS 2208:2023 "A Grade" certification.
- Gen3 Vision Glass can now be coated with Soft Solar Control Low-e coatings in industry first breakthrough.



Credit: ClearVue-Helios Product

## LICENCE PARTNERS & STRATEGIC PARTNERS



### erbas™ | erbas SUSTAIN™

ClearVue entered a collaboration agreement with erbas™ | erbas SUSTAIN™ to accelerate commercialisation and advance decarbonisation of the built environment. The collaboration focuses on integrating ClearVue's solar façade technology into commercial and institutional buildings, leveraging erbas™ expertise in sustainable building design and engineering support to drive new project opportunities and industry engagement.

### Emirates Glass

ClearVue signed a five-year agreement with architectural glass leader Emirates Glass to manufacture and distribute glazing products featuring ClearVue innovations, strengthening the Company's position in the United Arab Emirates alongside Alutec in Qatar.

### Kukyoung Glass and Metal Co., Ltd.

Kukyoung was formally authorised to market and deploy ClearVue's Solar Façade technology within its advanced glass products. The partnership opens access to Kukyoung's established customer network and supports property developers, architects, and government stakeholders in adopting Building Integrated Photovoltaic (BIPV) solutions. The combination of ClearVue's solar technology and Kukyoung's architectural glass expertise will drive new product innovations in façade systems for the Asian Market.

### Aria Glass Industries Private Ltd.

ClearVue signed a Manufacturing and Distribution Agreement with Aria Glass Industries Private Ltd, a subsidiary of Aria Holding, to manufacture and distribute ClearVue BIPV products in India. The Agreement furthers the partnership with Alutec announced on 1 August 2024, a portfolio company of Aria Holding, establishing dedicated Indian manufacturing capability through Aria's local operations.

# Project Highlights

## Overview

Sydney House will feature 45kWp of ClearVue Cladding, supporting its architectural vision, NABERS target and net-zero objectives.

## System Specifications

- **Location:** Sydney, Australia
- **Client:** SRG Global
- **Architect:** FJC Studio and BVN Architecture
- **Contractor:** Richard Crookes Constructions
- **Year:** 2027
- **Product:** ClearVue Cladding
- **Area:** 405m<sup>2</sup>
- **System Size:** 45kWp

## Overview

Canva's Sydney HQ will feature 660m<sup>2</sup> of integrated ClearVue Skylights, ClearVue Balustrades and a rooftop solar array to support its NABERS target.

## System Specifications

- **Location:** Sydney, Australia
- **Client:** Canva
- **Year:** 2026
- **Product:** ClearVue Skylight, ClearVue Balustrade, and conventional rooftop solar
- **Area:** 660m<sup>2</sup>
- **System Size:** 61kWp

## Overview

Rio Business Centre's 800m<sup>2</sup> retrofit integrates ClearVue BIPV glazing, solar cladding, bespoke framing and complete electrical design.

## System Specifications

- **Location:** Paphos, Cyprus
- **Architect:** GK Architect
- **Contractor:** JPB Group
- **Year:** 2026
- **Product:** ClearVue Cladding
- **Area:** 800m<sup>2</sup>
- **System Size:** 169kWp

# Chair's Letter to Shareholders

---



Dear Shareholders,

This has been a year of substantial change and progress for ClearVue Technologies.

As both Chair and a long-standing shareholder, I am very conscious that our share price remains below where we would all like it to be. While we are encouraged by the progress made across the business, ultimately that progress must translate into commercial growth and sustainable long-term value for our shareholders.

Over the past year, the Board and management have focused on positioning ClearVue for its next stage of growth. We have added significant capability to the Board and leadership team, advanced the certification and independent validation of our technology, broadened our product offering and expanded our international market presence and partner network.

The opportunity before us is significant. As cities become increasingly vertical, building façades represent an enormous and largely untapped opportunity for distributed renewable energy generation.

We are particularly encouraged by the opportunities emerging in Hong Kong and Singapore. The scale and density of these markets, together with their increasing focus on building performance, energy efficiency and decarbonisation, align strongly with ClearVue's technology. We believe the commercial opportunity across the region is significant.

I would particularly like to recognise the commitment of our Managing Director and Chief Executive Officer, Douglas Hunt, and our Chief Operating Officer, Tao Zhang. Both have spent significant periods away from their families developing strategic relationships with government, industry and commercial partners across Asia. Building a global business requires trust, presence and strong relationships, and on behalf of the Board, I thank Doug, Tao and their families for the commitment and sacrifices this has required.

Our priority in the year ahead is clear: **execution**. We must convert our growing pipeline into commercial outcomes, demonstrate repeatable market adoption and build a business capable of delivering sustainable returns for shareholders.

I thank the entire ClearVue team and my fellow directors for their dedication and commitment throughout the year.

Most importantly, I thank our shareholders. Many of you have supported ClearVue through periods that have tested your patience and confidence. We do not take that support for granted.

We enter the year ahead with internationally validated technology and a broader product platform. Alongside this, we have expanding global relationships and significant commercial opportunities. The Board remains firmly focused on translating these into tangible commercial outcomes and long-term shareholder value.

On behalf of the Board, thank you for your continued support.

Warm regards,

**Theresa Smits**  
Chair

# CEO's Letter to Shareholders

---



Dear Shareholders,

2026 has been a year of significant transition for ClearVue, best characterised by two words: restructure and rebuild.

Over the past 12 months, we have focused on laying the foundations required for commercialisation — strengthening our capabilities across certification, product design, project management, proposal development and delivery. ClearVue today is a very different company from the one it was 12 months ago, and that change is evident across all areas of our business.

Our project portfolio has continued to grow. The Canva headquarters in Sydney represents an important flagship project for ClearVue technology. Canva is one of the world's most innovative technology companies, and we are proud to have ClearVue BIPV products incorporated into its new headquarters. Other significant projects include the redevelopment of the Rio Business Centre in Cyprus and the R&D Greenhouse at Qatar University. Collectively, these projects demonstrate the breadth of applications for ClearVue's technology and its growing international reach.

We have also strengthened our Board with the appointments of Liang Ji, Andrew Lau and Prof. Rebecca Yang. Together, they bring extensive technical and commercial expertise, industry experience and international networks across markets important to ClearVue's future. Their willingness to join the Board is, I believe, a strong endorsement of the Company's technology, strategy and future direction.

Research and development have remained a key focus throughout the year, alongside the achievement of significant certifications across our product range. These certifications provide independent validation of product performance and, importantly, enable deployment across specific markets and applications.

Of particular significance has been our industry-first development enabling ClearVue Gen3 Vision Glass to incorporate soft-coat solar-control Low-E coatings. This allows architects and façade engineers to combine thermal performance, solar control and renewable energy generation within the glazing system.

The broader R&D and certification achievements delivered during the year continue to strengthen the technological differentiation of our product suite. They also demonstrate the depth of expertise within our team and our ability to engineer and certify solutions that provide tangible benefits to our customers. This capability is fundamental to building a scalable and commercially relevant technology platform.

ClearVue technology was also featured prominently during the Victorian Parliament's Inquiry into Construction Innovation, reflecting growing recognition of the role innovative technologies can play in the future of Australia's built environment. This recognition further reinforces the relevance of building-integrated photovoltaics as the industry looks for practical pathways to improve building performance and reduce energy consumption.

The achievements of FY2026 have established stronger foundations for the next stage of ClearVue's development.

Our focus is now firmly on converting those foundations — our technology, certifications, partnerships and growing project pipeline — into commercial outcomes.

We believe the strategy being executed positions ClearVue to play an important role in the transformation of the built environment, turning traditionally passive building surfaces into active, energy-generating assets.

I would like to thank our shareholders for their continued support, our Board for its guidance, and our employees, partners and collaborators for their commitment throughout a year of substantial change and progress.

Warm regards,



**Doug Hunt**  
Managing Director and Chief Executive Officer

The directors are pleased to present the audited consolidated financial report of ClearVue Technologies Limited

ABN 45 071 397 487 ("the Company") and its controlled entities ("the Group") for the year ended 30 June 2026.

The name of the directors in office at any time during or since the end of the year are:

- Ms Theresa Smits, Chair (appointed 8 July 2025, appointed to the chair 12 August 2025)
- Mr Douglas Hunt, Managing Director and Chief Executive Officer (appointed 12 August 2025)
- Mr Michael Pixley, Non-Executive Director (appointed 8 July 2025)
- Mr Liang Ji, Non-Executive Director (appointed 12 November 2025)
- Mr Andrew Lau, Non-Executive Director (appointed 23 March 2026)
- Prof. Rebecca Yang, Non-Executive Director (appointed 16 July 2026)
- Mr Victor Rosenberg, Non-Executive Chairperson, Non-Executive Director (resigned as Chairperson 12 August 2025, resigned from the board 29 November 2025)
- Mr Jamie Lyford, Executive Director (resigned 8 July 2025)
- Mr Charles Mowrey, Non-Executive Director (resigned 14 July 2025)
- Mr Gerd Hoenicke, Non-Executive Director (resigned 4 August 2025)

The qualifications, experience and special responsibilities of each director are as follows:



#### **MS THERESA SMITS**

Theresa Smits brings more than 35 years of business experience across banking, finance, administration, management, and marketing. Her career, built from hands-on experience, gives her strong strategic and operational capabilities in complex environments. She is highly organised, results-driven, and known for her adaptability and ability to build trusted relationships. An accomplished entrepreneur, she has founded and grown multiple successful ventures, including leading Broadband2U through to its acquisition by Superloop. Since 2007, she has transformed Eaton Services Group from a small regional operation into a major commercial cleaning and facilities management company across Australia's eastern seaboard, achieving over 2400% growth.



#### **MR DOUGLAS HUNT**

Douglas Hunt is an experienced international executive with a strong track record of building and scaling businesses across Asia Pacific. As former Chief Executive of Europcar Asia Pacific and Regional Director for Europcar International, he led operations across 31 countries and grew the business into a multi-market network generating more than \$110 million in annual revenue, supported by partnerships with leading airlines and hotel groups. Doug has deep expertise in international franchising and licensing, along with over seven years of experience in the renewable energy sector across the United States and Australia. As CEO and Managing Director he is driving the company's global commercialisation strategy and expanding international partnerships.



#### **MR MICHAEL PIXLEY**

Michael Pixley is an experienced merchant banker with over 30 years of experience across Asia, having begun his career in Singapore before relocating to Australia. He has extensive relationships with Asian businesses, individuals, and government entities, giving him strong regional insight. As a CEO and Director of both private and public companies, Mr. Pixley has built deep expertise in deal origination, structuring, and execution across real estate, infrastructure, and healthcare, leading complex transactions including mergers and acquisitions, IPOs, and debt and equity financings. Known for building long-term stakeholder relationships, he combines strategic leadership with a strong network and commercial acumen to deliver effective solutions across diverse industries.



#### **MR LIANG JI**

Liang Ji has been a pioneer in the solar energy industry since the late 1980s, contributing to the development of global photovoltaic (PV) standards. In early 1990s, he joined the Arizona State University team that established the first commercial PV module testing and certification laboratory in the United States, developing procedures and equipment that later underpinned widely used IEC standards. He joined the IEC Technical Committee for solar PV systems (TC82) in the early 2000s, has served as assistant secretary since 2004, and was lead author of the first concentrator PV standards, IEEE 1513 and IEC 62108. He was a Principal Engineer at Underwriters Laboratories specialising in PV product standards, advising globally on PV testing, reliability and performance.



#### **MR ANDREW LAU**

Andrew Lau brings over 20 years of ESG and engineering experience across Asia-Pacific, advising asset owners, developers and REITs on building performance, energy risk and long-term resilience. He has led projects across Greater China, Japan, Korea, Singapore and Southeast Asia, delivering measurable outcomes through HVAC optimisation, renewable integration, smart building systems and upgraded building envelopes. With specialist accreditation in building-integrated photovoltaics (BIPV), Andrew supports the practical application of emerging technologies. He currently leads ESG advisory initiatives at Colliers, helping clients futureproof assets through strong ESG frameworks and effective sustainability strategies.



#### **PROF. REBECCA YANG**

Professor Rebecca Yang is Professor and Doreen Thomas Fellow at the University of Melbourne and a recognised expert in building-integrated photovoltaics (BIPV), sustainable building technologies and renewable energy integration. Her research spans BIPV systems, net zero buildings, building energy performance, artificial intelligence and renewable energy applications in the built environment. Through collaboration with industry, government and research partners, Professor Yang has helped advance the development and commercial adoption of sustainable building technologies. She brings significant scientific, technical and sustainability expertise to the ClearVue Board.



#### **MR HARRY MILLER**

Harry Miller is Joint Company Secretary of ClearVue Technologies Limited and a Company Secretary and Corporate Advisor with Automic Group. He has more than eight years of company secretarial and accounting experience and currently acts as Company Secretary for a number of ASX-listed companies. His expertise includes corporate governance, ASX compliance, regulatory reporting and stakeholder communications. Harry works closely with boards and management to support governance best practice, statutory compliance and continuous disclosure. His experience spans board administration, shareholder communications and corporate reporting, helping listed companies maintain effective governance and compliance.

## REMUNERATION REPORT (AUDITED)

This report, which forms part of the Directors' report, outlines the remuneration arrangements in place for the key management personnel ("KMP") of ClearVue Technologies Limited for the financial year ended 30 June 2026. The information provided in this remuneration report has been prepared in accordance with the requirements of the Corporations Act 2001 and its Regulations and have been audited as required by Section 308(3C) of the Corporations Act 2001.

### KEY MANAGEMENT PERSONNEL

The KMP of the Company during or since the end of the financial year were as follows:

|                                                                 | PERIOD OF EMPLOYMENT                                                                                                      |
|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| <b>DIRECTORS</b>                                                |                                                                                                                           |
| Ms Theresa Smits, Non-Executive Chair                           | Appointed 8 July 2025 <sup>1</sup>                                                                                        |
| Mr Douglas Hunt, Executive Director and Chief Executive Officer | Appointed 12 August 2025                                                                                                  |
| Mr Michael Pixley, Non-Executive Director                       | Appointed 8 July 2025                                                                                                     |
| Mr Liang Ji, Non-Executive Director                             | Appointed 12 November 2025                                                                                                |
| Mr Andrew Lau, Non-Executive Director                           | Appointed 23 March 2026                                                                                                   |
| Mr Victor Rosenberg, Non-Executive Chair                        | Appointed 13 November 1995 to 29 November 2025 <sup>1</sup>                                                               |
| Mr Jamie Lyford, Executive Director                             | Appointed 10 February 2023 to 8 July 2025                                                                                 |
| Mr Charles Mowrey, Executive Director                           | Appointed 1 May 2023 to 14 July 2025                                                                                      |
| Mr Gerd Hoenicke, Non-Executive Director                        | Appointed 1 May 2023 to 4 August 2025                                                                                     |
| <b>KEY MANAGEMENT PERSONNEL</b>                                 |                                                                                                                           |
| Mr Doug Hunt, Chief Executive Officer                           | Appointed 1 July 2023 <sup>2</sup>                                                                                        |
| Mr Martin Deil, Chief Executive Officer                         | Appointed 1 June 2023 to 8 July 2025                                                                                      |
| Mr Geoff Edwards, Chief Financial Officer                       | Appointed 1 April 2023 to present                                                                                         |
| Ms Serjana Sadeq, Chief Strategy Officer                        | Appointed 13 August 2025                                                                                                  |
| Mr Tao Zhang, Chief Operating Officer                           | Appointed 1 August 2025                                                                                                   |
| Mr Earl Harper, Chief Commercial Officer                        | Appointed 1 June 2022 to 4 July 2025                                                                                      |
| Mr Clifton Smyth, Chief Business Development Officer            | Appointed 9 November 2022 to present                                                                                      |
|                                                                 | <sup>1</sup> On the 12 August 2025, Victor Rosenberg resigned from the chair and Theresa Smits was appointed to the chair |
|                                                                 | <sup>2</sup> On the 8 July 2025, Doug Hunt was promoted from Chief Operating Officer to Chief Executive Officer           |

### REMUNERATION POLICY

The Company's remuneration policy for its KMP has been developed by the Board taking into account the size of the Company, the size of the management team, the nature of the stage of development of the Company's current operations, and market conditions and comparable salary levels for companies of a similar size and operating in similar sectors.

In addition to considering the above general factors, the Board has also placed emphasis on the following specific issues in determining the remuneration policy for KMP:

- Sales contract awards;
- Technology development milestones; and
- The performance of the Company's shares as quoted on the Australian Securities Exchange.

### REMUNERATION COMMITTEE

Due to the current size of the Company, the Board did not implement a Remuneration Committee during the year, as such the Board of Directors of the Company is responsible for determining and reviewing compensation arrangements for the Directors and the executive team.

### REMUNERATION STRUCTURE

In accordance with best practice corporate governance, the structure of Non-Executive Director and executive remuneration is separate and distinct.

### NON-EXECUTIVE DIRECTOR REMUNERATION

The Board seeks to set aggregate remuneration at a level that provides the Company with the ability to attract and retain Directors of the highest calibre, whilst incurring a cost that is acceptable to shareholders.

The ASX Listing Rules specify that the aggregate remuneration of Non-Executive Directors shall be determined from time to time by a general meeting. The Constitution states that the Company may pay to the Non-Executive Directors a maximum total amount of director's fees, determined by the Company in general meeting, or until so determined, as the Directors resolve. Fees for the Non-Executive Directors are presently set at \$350,000 per annum including superannuation. These fees cover main board activities only. Non-Executive Directors may receive additional remuneration for other services provided to the Company.

The Non-Executive salary remuneration became effective from the date of appointment of the Company to the Official List of the Australian Securities Exchange.

### EXECUTIVE REMUNERATION

The Company's remuneration policy is to provide a fixed remuneration component and a short- and long-term performance-based component. The Board believes that this remuneration policy is appropriate given the considerations discussed in the section above and is appropriate in aligning executives' objectives with shareholder and business objectives.

### FIXED REMUNERATION

Fixed remuneration consists of base salaries, as well as employer contributions to superannuation funds and other non-cash benefits. Fixed remuneration is reviewed annually by the Board. The process consists of a review of company individual performance, relevant comparative remuneration externally and internally and, where appropriate, external advice on policies and practices.

### PERFORMANCE BASED REMUNERATION – SHORT TERM INCENTIVE

The Board has not implemented a system where Executives are entitled to annual cash bonuses. The Company may provide performance bonuses to Executives as determined by the Board from time to time.

### COMPANY PERFORMANCE SHARES AND RIGHTS

The Board has previously chosen to issue Performance Shares and Rights (where appropriate) to some executives as a key component of the incentive portion of their remuneration, in order to attract and retain the services of the executives and to provide an incentive linked to the performance of the Company.

### PERFORMANCE BASED REMUNERATION – LONG TERM INCENTIVE

In the future the Board may grant Options to executives and key consultants to provide incentive-based remuneration, with exercise prices at and/or above market share price (at the time of agreement). As such, Incentive Options granted to executives will generally only be of benefit if the executives perform to the level whereby the value of the Company increases sufficiently to warrant exercising the Incentive Options granted. It is considered the performance of the executives and the performance and value of the Company are closely related.

Vesting conditions associated with certain other performance rights and options have been set to align with selected strategic objectives of the Group that are considered relevant to the role of the individual to whom they are granted. Should these objectives be achieved, they are expected to have a positive impact on the performance of the Group and result in increased value for shareholders.

The Company prohibits executives entering into arrangements to limit their exposure to Performance Shares or Incentive Options granted as part of their remuneration package.

## Long-Term Incentive Plans

The Company has implemented an Employee Incentive Plan, a Loan Funded Share Plan, the Director and Employee, the ClearVue Officer, Employee and Adviser Share Plan and the Incentive Option Plan.

### **Employee Incentive Plan**

Under the Employee Incentive Plan, the Company may grant options to subscribe for Shares entitling the holder to be issued Shares on terms and conditions set by the Board at its discretion.

The material terms of the Employee Incentive Plan are as follows:

- a. The purpose of the Plan is to:
  - assist in the reward, retention and motivation of eligible persons;
  - to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to receive an equity interest in the form of Awards; and
  - to provide eligible persons with the opportunity to share in any future growth in value of the Company.
- b. The following persons can participate in the Plan if the Board makes them an offer to do so:
  - a director;
  - a full-time or part-time employee;
  - a contractor; or
  - a casual employee of the Company or an associated body corporate and includes a person who may become an eligible person within (a) above subject to accepting an offer of engagement for that role.
- c. Plan Options issued under the Plan are subject to the terms and conditions set out in the Rules, which include:
  - Vesting Conditions – which are time-based criteria, requirements or conditions (as specified in the offer and determined by the Board) which must be met prior to Awards vesting in a participant, which the Board may throughout the course of the period between the grant of an Award and its vesting, waive or accelerate as the Board considers reasonably appropriate;
  - Performance Conditions – which are conditions relating to the performance of the Group and its related bodies corporate (and the manner in which those conditions will be tested) as specified in an offer and determined by the Board; and
  - Exercise Conditions – which are criteria, requirements or conditions, as determined by the Board or under the Plan, which must be met (notwithstanding the satisfaction of any Vesting Conditions and/or Performance Conditions) prior to a Participant being entitled to exercise vested Awards in accordance with clauses 8 and 9 of the plan. Clause 8 prohibits the disposal of any incentive plan 12 months from the date the Plan Shares were issued to the holder, unless there is prior written approval of the Directors, or pursuant to an IPO or Takeover. Subject to the approval of the Directors, the employee may request that Plan Shares be allotted to a Related Entity of the employee under Clause 9.
- d. In accordance with ASIC Class Order 14/1000, the total Awards that may be issued under the Plan will not exceed 5% of the total number of Shares on issue. In calculating this limit, Awards issued to participants under the Plan other than in reliance upon this Class Order are discounted.
- e. The Board has the unfettered and absolute discretion to administer the Plan.
- f. Awards issued under the Plan are not transferable and will not be quoted on the ASX.

The Rules otherwise contain terms and conditions considered standard for long-term incentive plan rules of this nature.

There were no options issued under the Employee Incentive Plan during the year (2025:1,150,000).

### **Loan Funded Share Plan**

Under the Loan Funded Share Plan, the Company may grant Shares to a participant and may provide a loan to facilitate the acquisition of the Plan Shares. The terms of the loan and price of the Shares is determined by the Board.

The material terms of the Loan Funded Share Plan are as follows:

- a. The purpose of the Plan is to:
  - assist in the reward, retention and motivation of eligible persons;
  - to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to increase their ownership interest in the Company; and
  - to provide eligible persons with the opportunity to share in any future growth in value of the Company.
- b. The following persons can participate in the Plan if the Board makes them an offer to do so:
  - a director;
  - a full-time or part-time employee;
  - any other person who the Board determines is eligible to participate in the Plan.
- c. Loans offered under the Plan to facilitate the acquisition of Plan Shares will be interest free and end on 10 years from the Share Grant Date, or earlier in accordance with the Plan Rules.
- d. The total Shares that may be issued under the Plan in the previous five years, excluding any offers made in accordance with s708 of the Corporations Act, will not exceed 10% of the total number of Shares on issue.
- e. The Board has the unfettered and absolute discretion to administer the Plan.
- f. Shares issued under the Plan are not transferable.

The Rules otherwise contain terms and conditions considered standard for loan funded share plan rules of this nature.

There were no Shares issued under the Loan Funded Share Plan during the financial year.

During the year ended 30 June 2017, shares were issued under the Loan Funded Share Plan to then members of the Board. The following loans outstanding at 30 June 2026 and at the date of this report. Such loans are to be settled on or before 19 September 2027.

| HOLDER              | POSITION                       | NO.OF SHARES | LOAN AMOUNT |
|---------------------|--------------------------------|--------------|-------------|
| Mr Victor Rosenberg | Former Non -Executive Chairman | 1,000,000    | \$150,000   |
| Mr Jamie Lyford     | Former Executive Director      | 1,950,000    | \$292,000   |
| Mr Ian Rosenberg    | Former Non-Executive Director  | 125,000      | \$18,750    |

The remuneration report details the remuneration arrangements for KMP who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

### **ClearVue Officer, Employee and Adviser Share Plan**

The Company has also adopted a share plan called the 'ClearVue Officer, Employee and Adviser Share Plan' (OEASP) pursuant to which the Company may issue shares in the Company to participants. The difference between the OEASP and the Loan Funded Share Plan is that participants in the OEASP can be issued Shares at no cost and without loans being made by the Company. The OEASP was approved by Shareholders on 13 April 2017 (and is referenced at page 141 of the IPO Prospectus). A summary of the rules of the OEASP is set out below:

- a. (Eligibility): The Company may issue Shares to full-time or part-time officers, employees and advisers of the Company or any associated body corporate, or any other person who the Board determines is eligible to participate in the OEASP.
- b. (Consideration): No subscription price is payable for Shares issued under the OEASP. Shares issued under the OEASP vest on issue but cannot be transferred for 12 months. The Board may waive the transfer restrictions, including in circumstances where a takeover offer is made for the Company. Share issued under the OEASP carry with them the same rights to vote and receive dividends or capital distributions as other ordinary shares of the Company which are on issue.

The remuneration report details the remuneration arrangements for KMP who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

No shares were issued to key management personnel or directors under this plan for the year.

### ***Director and Employee Fee Plan***

The Company has adopted a Director and Employee Fee Plan (Fee Plan) to enable the Company to issue Shares to eligible participants in lieu of accrued cash remuneration. Eligible participants are full or part-time employees, officers, consultants, contractors and directors of the Company or any related entity or any nominee of such parties. Under the Fee Plan, eligible participants can elect to be paid some or all of the cash remuneration accrued to them by the issue of Shares. Any issues of Shares then made are at the discretion of the Board. The Fee Plan was approved by shareholders on 2 November 2020.

There were no shares issued under the Fee Plan during the year.

### ***Employee Securities Incentive Plan***

The Company has adopted an Employee Securities Incentive Plan (ESIP) to enable the Company to issue Options, Performance Rights, Shares and/or Loan Funded Shares to eligible participants.

Eligible participants are any Director or a person who is a full-time or part-time employee of the Company or its Related Bodies Corporate who is declared by the Board in its sole and absolute discretion to be eligible and any other person providing services to the Group and who is declared by the Board in its sole and absolute discretion to be eligible.

The material terms of the Employee Incentive Plan are as follows:

- a. The purpose of the Plan is to:
  - assist in the reward, retention and motivation of eligible persons;
  - to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to receive an equity interest in the form of Awards;
  - to provide eligible persons with the opportunity to share in any future growth in value of the Company.

- b. Terms of Options and Performance Rights

Each Option and/or Performance Right (Convertible Security) represents a right to acquire one or more Shares (for example, under an option or performance right), subject to the terms and conditions of the Plan. Prior to a Convertible Security being exercised a Participant does not have any interest (legal, equitable or otherwise) in any Share the subject of the Convertible Security by virtue of holding the Convertible Security. A Participant may not sell, assign, transfer, grant a security interest over or otherwise deal with a Convertible Security that has been granted to them unless otherwise determined by the Board. A Participant must not enter into any arrangement for the purpose of hedging their economic exposure to a Convertible Security that has been granted to them.

- c. Share Awards

The Board may from time to time make an invitation to an Eligible Participant to acquire Share Awards under the Plan. The Board will determine in its sole and absolute discretion the acquisition price (if any) for each Share Award which may be nil. The Share Awards may be subject to performance hurdles and/or vesting conditions as determined by the Board. Where Share Awards granted to a Participant are subject to performance hurdles and/or vesting conditions, the Participant's Share Awards will be subject to certain restrictions until the applicable performance hurdles and/or vesting conditions (if any) have been satisfied, waived by the Board or are deemed to have been satisfied under these Rules. Following the issue of a vesting notification to the Participant, the Share Awards held by the Participant will no longer be subject to any restrictions and may be transferred or sold by the Participant, subject to compliance with applicable laws, the Company's Securities Trading Policy and the terms of the Plan.

The conversion of the performance rights is dependent on the following:

**i) Class A Performance Rights**

- In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payment is equal to or greater than \$2,000,000 within a period of 24 months commencing on the date of issue of the Performance Rights (Issue Date) (Class A Milestone 1), each Class A Performance Right will vest and be convertible into one Share; or
- In the event that Class A Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class A Milestone 2), each Class A Performance Right will vest and be convertible into one Share; or
- In the event that neither Class A Milestone 1 or Class A Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class A Performance Right will vest and be convertible into one Share.

**ii) Class B Performance Rights**

- In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payment is equal to or greater than \$5,000,000 within a period of 24 to 36 months from the Issue Date (Class B Milestone 1), each Class B Performance Right will vest and be convertible into one Share; or
- In the event that Class B Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class B Milestone 2), each Class B Performance Right will vest and be convertible into one Share; or
- In the event that neither Class B Milestone 1 or Class B Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class B Performance Right will vest and be convertible into one Share.

**iii) Class C Performance Rights**

- In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payment is equal to or greater than \$10,000,000 within a period of 36 to 48 months from the Issue Date (Class C Milestone 1), each Class C Performance Right will vest and be convertible into one Share; or
- In the event that Class C Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class C Performance Right will vest and be convertible into one Share.

**iv) Class D Performance Rights**

- In the event that the participant assisting the company completes the development and testing of vision and spandrel glass to achieve an A2-s1, d0 fire rating confirmed by an independent third party testing, with such testing party approved by the company and certified to the EN13501.1 standard before the expiry date, each Class D Performance Right will vest and be convertible into a Share.

**v) Class E Performance Rights**

- In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and/or the participant has carriage of concluding an equity investment transaction before the expiry date, each Class E Performance Right will vest and be convertible into a Share.

**vi) Class F Performance Rights**

- In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and/or the participant has carriage of concluding an equity investment transaction before the expiry date, each Class F Performance Right will vest and be convertible into a Share.

**vii) Class G Performance Rights**

- In the event that the participant assists the company to complete an up-listing of its OTCQB US or ASX listing into the main US board of the NASDAQ or the NYSE before the expiry date or have commenced at least 3 months before the expiry date and such up-listing is completed within a further 6 months after the end of the expiry date, each Class G Performance Right will vest and be convertible into a Share.

## viii) Class H Performance Rights

- In the event the share price for the ordinary shares of the company reaches \$0.50 and maintains a volume weighted average of \$0.50 per ordinary share for at least 14 days with and before the expiry date, each Class H Performance Rights will vest and be convertible into a Share.

## ix) Class I Performance Rights

- In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve-month period before the expiry date, each Class I Performance Right will vest and be convertible into a Share.

## x) Class J Performance Rights

- In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve-month period before the expiry date, each Class J Performance Right will vest and be convertible into a Share.

## d. Loan Funded Shares

The Board may from time to time make an invitation to an Eligible Participant to acquire Loan Funded Shares under the Plan. The Board will determine in its sole and absolute discretion the acquisition price (if any) for each Loan Funded Shares which may be nil. The Loan Funded Shares may be subject to performance hurdles and/or vesting conditions as determined by the Board. Where Loan Funded Shares granted to a Participant are subject to performance hurdles and/or vesting conditions, the Participant's Loan Funded Shares will be subject to certain restrictions until the applicable performance hurdles and/or vesting conditions (if any) have been satisfied under these Rules. Following the issue of a vesting notification to the Participant, the Loan Funded Shares held by the Participant will no longer be subject to any restrictions and may be transferred or sold by the Participant, subject to compliance with applicable laws, the Company's Securities Trading Policy and the terms of the Plan. When the Company makes an invitation to an Eligible Participant to acquire Loan Funded Shares, the Company will also offer the Eligible Participant a Loan on terms and conditions to be determined by the Board, for the amount of the acquisition price of the Loan Funded Shares, for the purposes of acquiring all or part of the Loan Funded Shares the subject of the invitation. The loan amount may accrue interest as determined by the Board.

No shares were issued under the plan during the year (no shares were issued under this plan during the prior year).

## Incentive Option Plan

The Company has adopted an Incentive Option Plan to enable the company grant Options to any Director, full or part-time employee, or casual employee or contractor who falls within ASIC Class Order 14/1000, of the Company or an associated body corporate (Eligible Participant).

The material terms of the Incentive Option Plan are as follows:

- The purpose of the Plan is to:
  - assist in the reward, retention and motivation of eligible persons;
  - to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to receive an equity interest in the form of Awards;
  - to provide eligible persons with the opportunity to share in any future growth in value of the Company.
- The Board may, from time to time, in its absolute discretion, make a written offer to any Eligible Participant (including an Eligible Participant who has previously received an Offer) to apply for Options, upon the terms set out in the Plan and upon such additional terms and conditions as the Board determines (Offer).
- In exercising that discretion, the Board may have regard to the following (without limitation):
  - the Eligible Participant's length of service with the Group;
  - the contribution made by the Eligible Participant to the Group;
  - the potential contribution of the Eligible Participant to the Group; or
  - any other matter the Board considers relevant.
- For the avoidance of doubt, nothing in this document obliges the Company at any time to make an Offer, or further Offer, to any Eligible Participant.

- e. All offers and sales of Options shall be in compliance with U.S. securities laws, if applicable, as well as securities laws of states within the U.S., to the extent applicable.

During the year, no options were issued under the plan. 4,000,000 options were issued during the prior year.

### EXECUTIVE DIRECTOR SERVICE AGREEMENTS

The Company has entered into an agreement with Mr Doug Hunt dated 8 July 2025, pursuant to which the Company has engaged Mr D Hunt as Chief Executive Officer.

The material terms and conditions of the Employment Agreements are summarised below:

- a. Term: 24 months from commencement unless otherwise extended.
- b. Remuneration: From 8 July 2025, Mr Hunt received annual fee *exclusive* of statutory superannuation of approximately \$360,000 CPI adjusted annually from 1 July for the term of the agreement. The annual fee to increase by \$120,000 per annum if the share price 30 day rolling average reaches AUD\$0.35 per share. Mr Hunt joined the board 12 August and received an additional \$60,000 per annum as a director's fee *exclusive* of statutory superannuation.
- c. Incentive Programs: The Executives may participate in any incentive plan that the Company may introduce from time to time.
- d. Termination: The Company may terminate the employment of Mr Hunt:
  - i) Without cause with 3 months' notice;
  - ii) Immediately upon material breaches, criminal charges, misconduct, insolvency, or failure to remedy breaches within 24 hours.

### RELATIONSHIP BETWEEN REMUNERATION OF KMP AND SHAREHOLDER WEALTH AND EARNINGS

The Board anticipates that the Company will retain earnings (if any) and other cash resources for the development of its business activities. The Company does not currently have a policy with respect to the payment of dividends and returns of capital, however this will be reviewed on and in relation to the nature and amount of remuneration of KMP and dividends paid and returns of capital by the Company during the current and previous four financial years.

The Company did not consider appreciation of the Company's shares when setting remuneration.

The Board did issue Performance Shares and Performance Rights to Key Management Personnel and has implemented a Loan Funded Share Plan which will generally be of value if the Company's shares appreciate over time. However, it should be noted that all Director Shares granted under the Loan Funded Share Plan and all Performance Shares had been imposed in escrow (sale) restriction period for two years after listing. This is in line with the Company policy that Company securities be used for long-term incentives for Directors.



## AMOUNT OF REMUNERATION

Details of the remuneration of key management personnel of the consolidated entity are set out in the following tables. The proportion of remuneration linked to performance and the fixed proportion are as follows:


|                                 | FIXED REMUNERATION |      | AT RISK- STI |      | AT RISK - LTI |      |
|---------------------------------|--------------------|------|--------------|------|---------------|------|
|                                 | 2026               | 2025 | 2026         | 2025 | 2026          | 2025 |
| <b>DIRECTORS</b>                |                    |      |              |      |               |      |
| Ms Theresa Smits                | 100%               | -    | -            | -    | 100%          | -    |
| Mr Doug Hunt                    | 100%               | -    | -            | -    | 100%          | -    |
| Mr Michael Pixley               | 100%               | -    | -            | -    | 100%          | -    |
| Mr Liang Ji                     | 100%               | -    | -            | -    | -             | -    |
| Mr Andrew Lau                   | 100%               | -    | -            | -    | -             | -    |
| Mr V Rosenberg                  | 100%               | 100% | -            | -    | -             | 100% |
| Mr Lyford                       | 100%               | 100% | -            | -    | -             | -    |
| Mr Hoenicke                     | 100%               | 100% | -            | -    | -             | -    |
| Mr Mowrey                       | 100%               | 100% | -            | -    | -             | -    |
| <b>KEY MANAGEMENT PERSONNEL</b> |                    |      |              |      |               |      |
| Mr Doug Hunt (CEO)              | 100%               | 100% | -            | -    | 100%          | 100% |
| Mr Edwards (CFO)                | 100%               | 100% | -            | -    | -             | -    |
| Mr Smyth (CBDO)                 | 100%               | 100% | -            | -    | 100%          | 100% |
| Mr Zhang (COO)                  | 100%               | -    | -            | -    | -             | -    |
| Ms Sadeq (CSO)                  | 100%               | -    | -            | -    | -             | -    |
| Mr Lyford (COO)                 | 100%               | 100% | -            | -    | -             | -    |
| Mr Deil (CEO)                   | 100%               | 100% | -            | -    | -             | 100% |
| Mr Harper (CCO)                 | 100%               | 100% | -            | -    | -             | 100% |

# DIRECTORS' REPORT - REMUNERATION REPORT

2025

|                          | SHORT-TERM BENEFITS  |                      |              |                     | POST-EMPLOYMENT BENEFITS |       | LONG-TERM BENEFITS |        | EQUITY-SETTLED SHARE-BASED PAYMENTS |                              |           |
|--------------------------|----------------------|----------------------|--------------|---------------------|--------------------------|-------|--------------------|--------|-------------------------------------|------------------------------|-----------|
|                          | Salary, Fees & Leave | Profit Share & Bonus | Non-Monetary | Other*              | Super                    | Other | Incentive Plans    | Leave  | Shares / Units                      | Options / Performance Shares |           |
| DIRECTORS                |                      |                      |              |                     |                          |       |                    |        |                                     |                              |           |
| Mr V Rosenberg           | 308,920              | -                    | -            | -                   | 11,500                   | -     | -                  | -      | -                                   | -                            | 320,420   |
| Mr Lyford                | 341,485              | -                    | -            | 10,000 <sub>2</sub> | 29,387                   | -     | -                  | 26,339 | -                                   | -                            | 407,211   |
| Mr Hoenicke              | 60,000               | -                    | -            | -                   | -                        | -     | -                  | -      | -                                   | -                            | 60,000    |
| Mr Mowrey                | 522,255              | -                    | -            | 48,641 <sub>3</sub> | 9,245                    | -     | -                  | 9,482  | -                                   | -                            | 589,623   |
| KEY MANAGEMENT PERSONNEL |                      |                      |              |                     |                          |       |                    |        |                                     |                              |           |
| Mr Deil (CEO)            | 435,839              | -                    | -            | -                   | 75,400                   | -     | -                  | 12,357 | -                                   | 99,410                       | 623,006   |
| Mr Edwards (CFO)         | 200,000              | -                    | -            | -                   | 23,000                   | -     | -                  | 9,487  | -                                   | 155,912                      | 388,399   |
| Mr Harper (CCO)          | 212,121              | -                    | -            | -                   | 24,394                   | -     | -                  | 11,795 | -                                   | -                            | 248,310   |
| Mr Smyth (CBDO)          | 370,579              | -                    | -            | -                   | -                        | -     | -                  | -      | -                                   | -                            | 370,579   |
| Mr Doug Hunt (COO)       | 312,488              | -                    | -            | -                   | -                        | -     | -                  | -      | -                                   | -                            | 312,488   |
|                          | 2,763,387            | -                    | -            | 58,641              | 172,926                  | -     | -                  | 69,460 | -                                   | 255,322                      | 3,320,036 |

1. Mr Rosenberg's salary fees and leave include a consulting fee to Luminate Pty Ltd (an entity associated with Mr Rosenberg) of \$227,050 and director's fee of \$86,000.
2. Relates to motor vehicle allowances.



# DIRECTORS' REPORT - REMUNERATION REPORT

2026

|                                 | SHORT-TERM BENEFITS  |                      |              |                     | POST- EMPLOYMENT BENEFITS |       | LONG-TERM BENEFITS |        | EQUITY-SETTLED SHARE-BASED PAYMENTS |                              |           |
|---------------------------------|----------------------|----------------------|--------------|---------------------|---------------------------|-------|--------------------|--------|-------------------------------------|------------------------------|-----------|
|                                 | Salary, Fees & Leave | Profit Share & Bonus | Non-Monetary | Other*              | Super                     | Other | Incentive Plans    | Leave  | Shares / Units                      | Options / Performance Shares |           |
| DIRECTORS                       |                      |                      |              |                     |                           |       |                    |        |                                     |                              |           |
| Ms Theresa Smits                | 66,267               | -                    | -            | -                   | -                         | -     | -                  | -      | 40,440                              | 127,008                      | 233,715   |
| Mr Doug Hunt <sup>4</sup>       | 459,072              | 50,000               | -            | -                   | -                         | -     | -                  | -      | -                                   | -                            | 509,072   |
| Mr Michael Pixley               | 55,000               | -                    | -            | -                   | -                         | -     | -                  | -      | -                                   | 127,008                      | 182,008   |
| Mr Liang Ji                     | 38,167               | -                    | -            | -                   | -                         | -     | -                  | -      | -                                   | -                            | 38,167    |
| Mr Andrew Lau                   | 16,452               | -                    | -            | -                   | -                         | -     | -                  | -      | -                                   | -                            | 16,452    |
| Mr V Rosenberg <sup>1</sup>     | 80,036               | -                    | -            | -                   | 3,800                     | -     | -                  | -      | -                                   | -                            | 83,836    |
| Mr Lyford                       | 8,430                | -                    | -            | 215                 | 3,487                     | -     | -                  | -      | -                                   | -                            | 12,132    |
| Mr Mowrey                       | 142,275              | -                    | -            | 22,070 <sup>3</sup> | -                         | -     | -                  | -      | -                                   | -                            | 164,345   |
| KEY MANAGEMENT PERSONNEL        |                      |                      |              |                     |                           |       |                    |        |                                     |                              |           |
| Mr Doug Hunt (CEO) <sup>4</sup> | 9,677                | -                    | -            | -                   | -                         | -     | -                  | -      | -                                   | -                            | 9,677     |
| Mr Edwards (CFO)                | 200,000              | -                    | -            | -                   | 24,000                    | -     | -                  | 14,872 | -                                   | -                            | 238,872   |
| Mr Smyth (CBDO)                 | 367,569              | -                    | -            | -                   | -                         | -     | -                  | -      | -                                   | -                            | 367,569   |
| Mr Zhang (COO)                  | 174,166              | -                    | -            | -                   | 20,900                    | -     | -                  | 10,473 | -                                   | -                            | 205,539   |
| Ms Sadeq (CSO)                  | 137,533              | -                    | -            | 16,145              | 16,292                    | -     | -                  | 8,872  | -                                   | -                            | 178,842   |
| Mr Lyford (COO)                 | 253,800              | -                    | -            | 4,785               | 27,227                    | -     | -                  | -      | -                                   | -                            | 285,812   |
| Mr Deil (CEO)                   | 175,753              | -                    | -            | -                   | 36,134                    | -     | -                  | -      | -                                   | -                            | 211,887   |
| Mr Harper (CCO)                 | 83,057               | -                    | -            | -                   | 6,369                     | -     | -                  | -      | -                                   | -                            | 89,426    |
|                                 | 2,267,254            | 50,000               | -            | 43,215              | 138,209                   | -     | -                  | 34,217 | 40,440                              | 254,016                      | 2,827,351 |

1. Mr Rosenberg's salary fees and leave include a consulting fee to Luminate Pty Ltd (an entity associated with Mr Rosenberg) of \$227,050 and director's fee of \$86,000.
2. Relates to motor vehicle allowances.
3. Relates to health insurance.
4. On the 8 July 2025, Doug Hunt was promoted from COO to CEO. On the 12 August 2025, Doug Hunt was appointed to the board of directors.

## SHAREHOLDING

The number of shares held during the financial year by each director and members of key management personnel of the Company, including their personally related parties, is set out below:

| ORDINARY SHARES          |                                                           |                                        |           |                      |                                                         |
|--------------------------|-----------------------------------------------------------|----------------------------------------|-----------|----------------------|---------------------------------------------------------|
|                          | BALANCE AT THE START<br>OF THE YEAR /<br>APPOINTMENT DATE | RECEIVED AS PART<br>OF<br>REMUNERATION | ADDITIONS | DISPOSALS /<br>OTHER | BALANCE AT THE END<br>OF THE YEAR /<br>RESIGNATION DATE |
| DIRECTORS                |                                                           |                                        |           |                      |                                                         |
| Ms Theresa Smits         | 6,351,000                                                 | 288,864                                | 9,000     | -                    | 6,648,864                                               |
| Mr V Rosenberg           | 27,175,198                                                | -                                      | -         | -                    | 27,175,198                                              |
| Mr Lyford                | 9,510,000                                                 | -                                      | -         | -                    | 9,510,000                                               |
| Mr Hoenicke              | 236,900                                                   | -                                      | -         | -                    | 236,900                                                 |
| Mr Mowrey                | 200,000                                                   | -                                      | -         | -                    | 200,000                                                 |
|                          | 43,473,098                                                | 288,864                                | 9,000     | -                    | 43,770,962                                              |
| KEY MANAGEMENT PERSONNEL |                                                           |                                        |           |                      |                                                         |
| Mr Zhang                 | 100,000                                                   | -                                      | -         | -                    | 100,000                                                 |
| Mr Edwards               | 40,000                                                    | -                                      | -         | -                    | 40,000                                                  |
| Mr Smyth                 | 500,000                                                   | -                                      | -         | 80,000               | 420,000                                                 |
| Mr Harper                | 1,215,000                                                 | -                                      | -         | -                    | 1,215,000                                               |
| Mr Deil                  | 2,084,000                                                 | -                                      | -         | -                    | 2,084,000                                               |
|                          | 3,939,000                                                 | -                                      | -         | 80,000               | 3,859,000                                               |



## CONVERTIBLE SECURITY HOLDING

The number of convertible securities held during the financial year by each director and members of key management personnel of the Company, including their personally related parties, is set out below:

## OPTIONS

No options were issued to directors or key management personnel.

### OPTIONS

|                                 | BALANCE AT THE START<br>OF THE YEAR /<br>APPOINTMENT DATE | GRANTED | EXERCISED/LAPSED | FREE<br>ATTACHING<br>OPTIONS | BALANCE AT THE<br>END OF THE YEAR /<br>RESIGNATION DATE |
|---------------------------------|-----------------------------------------------------------|---------|------------------|------------------------------|---------------------------------------------------------|
| <b>DIRECTORS</b>                |                                                           |         |                  |                              |                                                         |
| Mr Hunt                         | 500,000                                                   | -       | -                | -                            | 500,000                                                 |
| Mr V Rosenberg                  | 1,020,000                                                 | -       | 20,000           | -                            | 1,000,000                                               |
| Mr Hoenicke                     | 1,000,000                                                 | -       | -                | -                            | 1,000,000                                               |
| Mr Mowrey                       | 1,066,667                                                 | -       | 66,667           | -                            | 1,000,000                                               |
| Mr Lyford                       | 1,006,666                                                 | -       | 6,666            | -                            | 1,000,000                                               |
|                                 | 4,593,333                                                 | -       | 93,333           | -                            | 4,500,000                                               |
| <b>KEY MANAGEMENT PERSONNEL</b> |                                                           |         |                  |                              |                                                         |
| Mr Zhang                        | 150,000                                                   | -       | -                | -                            | 150,000                                                 |
| Mr Edwards                      | 513,333                                                   | -       | 13,333           | -                            | 500,000                                                 |
| Mr Deil                         | 3,333,333                                                 | -       | 3,333,333        | -                            | -                                                       |
| Mr Harper                       | 13,333                                                    | -       | 13,333           | -                            | -                                                       |
|                                 | 4,009,999                                                 | -       | 3,359,999        | -                            | 650,000                                                 |

## PERFORMANCE SHARES

During the year, 3,000,000 performance rights were issued as remuneration to directors.

### PERFORMANCE RIGHTS

|                                 | BALANCE AT THE START<br>OF THE YEAR/<br>APPOINTMENT DATE | GRANTED          | EXERCISED | EXPIRED /<br>FORFEITED /<br>OTHER | BALANCE AT THE END<br>OF THE YEAR /<br>RESIGNATION DATE |
|---------------------------------|----------------------------------------------------------|------------------|-----------|-----------------------------------|---------------------------------------------------------|
| <b>DIRECTORS</b>                |                                                          |                  |           |                                   |                                                         |
| Ms Smits                        | -                                                        | 1,500,000        | -         | -                                 | 1,500,000                                               |
| Mr Pixley                       | -                                                        | 1,500,000        | -         | -                                 | 1,500,000                                               |
| Mr Hunt                         | 1,000,000                                                | -                | -         | -                                 | 1,000,000                                               |
| Mr V Rosenberg                  | 10,000,000                                               | -                | -         | 10,000,000                        | -                                                       |
|                                 | <b>11,000,000</b>                                        | <b>3,000,000</b> | <b>-</b>  | <b>10,000,000</b>                 | <b>4,000,000</b>                                        |
| <b>KEY MANAGEMENT PERSONNEL</b> |                                                          |                  |           |                                   |                                                         |
| Mr Smyth                        | 1,500,000                                                | -                | -         | 1,500,000                         | -                                                       |
| Mr Harper                       | 2,000,000                                                | -                | -         | 2,000,000                         | -                                                       |
|                                 | <b>3,500,000</b>                                         | <b>-</b>         | <b>-</b>  | <b>3,500,000</b>                  | <b>-</b>                                                |

## OTHER TRANSACTIONS WITH KEY MANAGEMENT PERSONNEL AND THEIR RELATED PARTIES

|                                                                       | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-----------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Consultancy services from Luminate Pty Ltd <sup>1</sup>               | 48,369                            | 208,920                           |
| Fees from SACCHS Pty Ltd for COO, CEO and Board services <sup>2</sup> | 518,749                           | -                                 |
| Fees from Nepix Pty Ltd for Board services <sup>3</sup>               | 55,000                            | -                                 |

1 A director related entity of Mr Rosenberg

2 A director related entity of Mr Hunt

3 A director related entity of Mr Pixley

## RECEIVABLE AND PAYABLE TO RELATED PARTIES

All transactions were made on normal commercial terms and conditions and at market rates.

|                                                   | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|---------------------------------------------------|-----------------------------------|-----------------------------------|
| Share plan reserve to Mr V Rosenberg <sup>1</sup> | 150,000                           | 150,000                           |
| Share plan reserve to Mr I Rosenberg <sup>2</sup> | 18,750                            | 18,750                            |
| Share plan reserve to Mr Lyford <sup>3</sup>      | 292,500                           | 292,500                           |
| Accrual to Ms Theresa Smits                       | 66,267                            | -                                 |
| Accrual to Mr Andrew Lau                          | 16,452                            | -                                 |
| Accrual to Mr Liang Ji                            | 38,167                            | -                                 |
| Amount owing to Mr Doug Hunt                      | 3,771                             | -                                 |
| Amount owing from Mr Doug Hunt                    | 7,802                             | -                                 |
| Amount owing to Ms Serjana Sadeq                  | 33                                | -                                 |

1. For the purchase of 1,000,000 shares at an issue price of \$0.15

2. For the purchase of 125,000 shares at an issue price of \$0.15

3. For the purchase of 1,950,000 shares at an issue price of \$0.15

- End of Remuneration Report -

## PRINCIPAL ACTIVITIES

The principal activities of the Company during the year were developing a sales and leads pipeline for the Company's products, licensing activities to appoint new manufacturers and distributors, as well as research and development activities applied to the Company's world leading solar glass and BIPV technology. There were no significant changes in the nature of the activities of the Company during the financial year.

## REVIEW OF OPERATIONS AND FINANCIAL RESULTS

The operating loss of the Group for the financial year after providing for income tax amounted to \$11,861,917 (2025: \$11,584,706), with net cash used in operating activities of \$8,685,191 (2025: \$9,231,873).

### **Product Advancements:**

- September 2025: ClearVue announced the successful prototyping, trial manufacture and independent validation of its Gen3 Solar Vision Glass. Early testing by the Solar Energy Research Institute of Singapore (SERIS) showed more than 66% higher energy output per square metre than ClearVue's previous generation, at over 50 W/m<sup>2</sup>. ClearVue also reported that processing time for a double-glazed unit was cut by more than half, driving a material reduction in production costs, and that required components fell from 17 to 7.
- October 2025: ClearVue expanded ClearVue-Helios into modular solar carports, carports and canopies, in which the metal-backed panels form the roof on a prefabricated steel structure. ClearVue reported up to 590 Wp per panel, a payback of under four years before subsidies, up to 70% faster installation, and a cost similar to that of standard carports.
- March 2026: ClearVue and manufacturing partner Helios Power achieved IEC 61730 and IEC 61215 certification for the new metal-backed rooftop and car park solar panels, positioning ClearVue to commence Australian Clean Energy Council (CEC) certification.
- May 2026: ClearVue's in-house designed Thermal Management Junction Box (model CV-JB-SGT-001) achieved IEC 62790 certification from TÜV SÜD. Rated at 1,000 V and 30 A with an IP68 waterproof rating, it is designed to prevent hotspots in façade cavities.
- June 2026: ClearVue's Gen3 Solar Vision Glass passed EN 1279-5:2018 testing, confirming the long-term sealing performance of its insulating glass unit, including its patent-applied-for design that allows power cables to pass through the seal, and its compatibility with industry-standard aluminium spacers.
- June 2026: ClearVue's complete double-glass product range (Vision Glass, Solar Skylight, Solar Balustrade, Solar Cladding and Solar Spandrel) achieved Grade A classification, the highest rating, under AS/NZS 2208:2023, the safety glazing standard referenced in the National Construction Code and AS 1288.

### **Strategic Partnerships:**

- July 2025: ClearVue signed a non-binding MOU with LandVac, a subsidiary of LandGlass Technology Co. Ltd, setting out the parties' intent to form a Hong Kong-based joint venture. The JV would hold the IP for all co-developed innovations, with both parties contributing their technologies, expertise and global networks. Under the MOU, the parties will research, develop, manufacture and commercialise a new range of solar vacuum-insulated glazing (Solar VIG). The range will be co-branded and marketed through both companies' global networks, with LandVac already selling in more than fifty countries. Each party will use the other's technology exclusively in solar VIG products.
- July 2025: ClearVue entered a collaboration agreement with erbas<sup>TM</sup> | erbas SUSTAIN<sup>TM</sup> to accelerate commercialisation and advance decarbonisation of the built environment. The collaboration focuses on integrating ClearVue's solar façade technology into commercial and institutional buildings, leveraging erbas<sup>TM</sup> expertise in sustainable building design and engineering support to drive new project opportunities and industry engagement.
- March 2026: ClearVue expanded its strategic manufacturing and R&D partnership with Helios Power for metal-backed rooftop and carpark solar panels. Their continuing program focused on installation efficiency, product performance, electrical safety, lower installation costs and international certification.

### **Licence Partner Agreements:**

- August 2025: ClearVue signed a five-year agreement with architectural glass leader Emirates Glass to manufacture and distribute glazing products featuring ClearVue innovations, strengthening the Company's position in the United Arab Emirates alongside Alutec in Qatar.
- November 2025: ClearVue signed a three-year Licence Partner Agreement with Kukyoung Glass and Metal Co., Ltd. The agreement authorised Kukyoung to market and deploy ClearVue Solar Façade technology in South Korea and supported joint research and product development.

- May 2026: ClearVue entered the Indian market through a manufacturing and distribution agreement with Aria Glass Industries Private, part of the Aria Holding group. The agreement grants Aria Glass the right to manufacture ClearVue's products in India and to distribute them domestically and internationally on a non-exclusive basis, for an initial term of three years with options to extend.

### **Research, Development and Government Engagement:**

- July 2025: ClearVue joined a landmark \$20 million greenhouse research project led by RMIT University, contributing its solar glass technology and scientific expertise. The five-year program began on 1 July 2025.
- March 2026: ClearVue made a written submission to, and gave evidence at the public hearing of, the Victorian Parliament Legislative Assembly Environment and Planning Committee inquiry into renewable and affordable energy for apartments and other multi-unit dwellings.
- March 2026: ClearVue commenced project-specific measurement and verification testing at BCA Skylab in connection with two large-scale commercial building opportunities in Asia, measuring the thermal performance and energy generation of Gen3 Solar Vision Glass against conventional and incumbent glazing under real-world conditions, and commenced project-specific local certification for a residential tower in the Middle East.
- May 2026: ClearVue and the University of Melbourne were awarded A\$280,000 Australian Research Council Linkage Grant for a three-year research program. The program will design, model, construct and test new techniques to increase solar electricity generation in transparent glass. If successful, these technologies could be incorporated into future versions of ClearVue's solar windows.
- July 2026: Qatar University commenced an independent validation of ClearVue's transparent PV glazing in a greenhouse environment. The study measures energy generation, internal temperature reduction, light transmission, cooling load and greenhouse productivity.

### **Noteworthy Projects:**

- September 2025: Double-glazed solar skylight units were delivered to the World Bank Administration Building in Abuja, Nigeria for installation. Compatibility testing was completed at Sydney House, formerly City Tattersalls Club, in Sydney, Australia, with the Company engaging on cabling and electrical design.
- March 2026: The construction phase of the pure black Solar Spandrel installation at Enex100, 100 St Georges Terrace in Perth, Australia was completed. The project moved into close-out, with commissioning and grid integration scheduled for the building's annual shutdown period.
- March 2026: The Prefabulous Net Zero Cabin at Inverloch, Victoria, featuring ClearVue Gen2 Solar Vision Glass, was delivered to its final client location ready for rooftop installation of 28 ClearVue-Helios panels with a combined system capacity of ~16.52 kWp, acting as a second skin, waterproofing and extending the life of the roof material.
- May 2026: ClearVue secured its first European commercial project at the Rio Business Centre in Paphos, Cyprus. The approximately A\$305,000 contract covered more than 800 m<sup>2</sup> of BIPV glazing and framing, with an estimated capacity of 169 kW and forecast annual generation of approximately 139 MWh.
- July 2026: ClearVue executed a contract with Infinity Constructions Group with an expected value of approximately A\$600,000 for supply to the new Canva Headquarters in Surry Hills. The contract is for the supply of approximately 660 m<sup>2</sup> of Solar Skylights, Solar Balustrades and a rooftop array, with an estimated capacity of ~61 kW and forecast annual generation of approximately 76,000 kWh, contributing to the building's targeted NABERS Energy rating.

### **Corporate and Governance:**

- August 2025: Douglas Hunt joined ClearVue's Board as Managing Director while serving as CEO. Theresa Smits was appointed interim Non-Executive Chairperson following Victor Rosenberg's transition from Chair to Non-Executive Director.
- November 2025: Founder Victor Rosenberg retired from the Board at the Annual General Meeting held on 28 November 2025. Theresa Smits was confirmed as Non-Executive Chairperson.
- November 2025: Liang Ji, formerly a Principal Engineer at Underwriters Laboratories and a contributor to international photovoltaic standards, was appointed a Non-Executive Director.
- March 2026: Andrew Lau, Director of ESG Advisory at Colliers Asia, was appointed a Non-Executive Director, bringing more than 22 years of sustainability and carbon reduction experience across Asian markets.
- July 2026: Professor Rebecca Yang was appointed an Independent Non-Executive Director, bringing extensive expertise in building-integrated photovoltaics, solar façade technologies, and international research collaboration.

## Capital Management:

- October 2025: ClearVue completed an equity placement raising approximately \$4.6 million, supported by institutional and other investors internationally and domestically, co-lead managed by RM Capital and Spark+.
- March 2026: ClearVue established an A\$3 million facility with Riverfort Global Opportunities PCC Ltd at 8% interest, secured over its R&D tax incentive. At 30 June 2026, A\$1.9 million was drawn and A\$1.1 million remained available.
- June 2026: ClearVue announced an approximately A\$6 million Placement and Share Purchase Plan. It received approximately A\$4.8 million before costs by issuing 42,054,348 shares at A\$0.115. Proceeds supported certification, marketing, intellectual property and international business development.

## Highlights:

- **Product Certification and Market Credibility:** The most significant certification programme in the Company's history was delivered, spanning AS/NZS 2208:2023, EN 1279-5:2018, IEC 62790, IEC 61730 and IEC 61215, confirming that ClearVue's energy-generating products perform to the same standards expected of conventional high-quality architectural glazing and removing risk from customer specification decisions.
- **Geographic Expansion:** ClearVue secured its first European project in Cyprus, entered the Indian manufacturing market through Aria Glass Industries, strengthened its Middle East position through Emirates Glass, and established an operating presence in Hong Kong.
- **Commercial Validation:** Selection for the new Sydney headquarters of Canva, one of the world's leading technology companies provided a reference project for the corporate, commercial and global retrofit markets.
- **Commercialisation Pipeline:** The project pipeline grew beyond 80 projects with approximately 60 full proposals submitted, supported by new customer relationship management software, expanded business development capability across Australia, Hong Kong and Europe, and approximately 15 new project enquiries per month by year end.
- **R&D Investment and Validation:** The Australian Research Council Linkage Grant with The University of Melbourne, receipt of the Research and Development Tax Incentive, and progression of the world-first full-scale façade fire testing programme underpin the Company's long-term technology leadership in BIPV solutions.

## Material Business Risks

Material business risks faced by the Company that are likely to have an effect on the financial prospects of the Company and how the company manage these risks include:

- Insufficient capital – given the reliance on capital, there is a risk of delays to projects, the research and development program and commercialisation strategy. There is also a going concern risk. This has been mitigated by way of operational reviews, cost cutting measures, capital raising activities and focus on investor relations.
- Higher than expected warranty claims – although not a current significant risk, as the Company commercialises, high warranty claims may result in unexpected cash outflows and lower gross margins. This is mitigated with back-to-back agreements with OEM suppliers and due diligence and a selection of reputable and high quality OEMs. As this risk becomes imminent, the Company has a quality management strategy ready to activate.
- Misappropriation of intellectual property – given intellectual property is the primary asset of the Company, any significant misappropriation of intellectual property may result in a loss of competitive advantage, commoditisation of the product and litigation costs. This has been mitigated by way of an extensive patent portfolio, patent insurance and continuing innovation.
- Disruption to raw material supply – given the reliance on raw material supply from OEMs to enable the commercialisation of the Company and the continuing research and development program, this may result in project delays, higher input costs and missed milestones. This being mitigated by diversification of OEM's, secondary sourcing, forward purchasing and ongoing audits, reviews and relationship management with OEMs.

## ADDITIONAL INFORMATION

|                                        | 2026         | 2025         | 2024         | 2023        | 2022        |
|----------------------------------------|--------------|--------------|--------------|-------------|-------------|
| Revenue                                | 108,484      | 249,925      | 39,811       | 63,310      | 287,613     |
| EBITDA                                 | (8,534,226)  | (10,240,209) | (11,906,897) | (7,127,567) | (3,583,633) |
| EBIT                                   | (11,778,845) | (11,551,571) | (12,514,067) | (7,484,316) | (3,791,365) |
| Loss after income tax                  | (11,861,917) | (11,584,706) | (12,491,037) | (7,497,092) | (3,806,151) |
| Share price (\$)                       | 0.09         | 0.23         | 0.41         | 0.165       | 0.20        |
| Dividend (cents per share)             | -            | -            | -            | -           | -           |
| Basic loss per share (cents per share) | (4.0)        | (4.5)        | (5.4)        | (3.5)       | (1.8)       |

## DIVIDENDS

No dividend has been declared or paid since the start of financial year. The Directors do not recommend the declaration of a dividend.

## SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

During the year ending 30 June 2026 the following changes were made

- Winding up of the Opticrop operation was commenced and all associated staff were terminated.
- On 4 March 2026, a secured \$3m funding facility was secured with Riverfort Global Opportunities PCC Ltd (refer note 10)
- On 13 October 2025, \$4.57m was raised by way of a share placement with issue of 25,689,625 ordinary shares at \$0.18, with one free attaching option for each share, with an exercise price of \$0.20 expiring 1 September 2026.
- On 23 June 2026, \$4.8m was raised by way of a share placement with the issue of 45,054,348 ordinary shares at \$0.115, with a one for free attaching option for each share, with an exercise price \$0.115 expiring 3 years from issue date (issuance subject to shareholder approval at an EGM to be held 12 October 2026).
- On 8 July 2025, Theresa Smits and Michael Pixley were appointed to the board.
- On 8 July 2025, Jamie Lyford resigned from the board.
- On 14 July 2025, Charles Mowrey resigned from the board.
- On 4 August 2025, Gerd Hoenicke resigned from the board.
- On 12 August 2025, Doug Hunt was appointed to the board.
- On 12 November 2025, Liang Ji was appointed to the board
- On 29 November 2025, Victor Rosenberg resigned from the board.
- On 23 March 2026, Andrew Lau was appointed to the board.

No other significant changes in the state of affairs from prior year.

## EVENT SUBSEQUENT TO THE END OF THE REPORTING PERIOD

Professor Rebecca Yang was appointed to the Board of Directors on 16 July 2026.

On 21 July 2026 the Company completed a Share Purchase Plan receiving a total of \$1,291,000 for 14,670,426 ordinary shares with one free attaching option for each share with an exercise price of \$0.115 expiring three years from their issue date. The free attaching options will be issued at a later date following shareholder approval at an upcoming General Meeting.

On 13 July 2026 the company repaid Riverfort Global \$600,000 principal and \$24,329 interest.

## FUTURE DEVELOPMENTS

A discussion of likely developments in the Company and the expected results of those operations is set out in the Non-Executive Chair's letter.

## DIRECTOR'S MEETINGS

The meetings of the Company's Board of Directors held during the year ended 30 June 2026. The number of meetings attended by each director were:

|                | BOARD MEETING      |          | AUDIT & COMPLIANCE COMMITTEE MEETINGS <sup>1</sup> |          |
|----------------|--------------------|----------|----------------------------------------------------|----------|
|                | Eligible to attend | Attended | Eligible to attend                                 | Attended |
| Ms Smits       | 12                 | 12       | -                                                  | -        |
| Mr Hunt        | 10                 | 10       | -                                                  | -        |
| Mr Pixley      | 10                 | 10       | -                                                  | -        |
| Mr Ji          | 6                  | 4        | -                                                  | -        |
| Mr Lau         | 3                  | 3        | -                                                  | -        |
| Mr V Rosenberg | 6                  | 6        | -                                                  | -        |
| Mr Lyford      | -                  | -        | -                                                  | -        |
| Mr Hoenicke    | 1                  | 1        | -                                                  | -        |
| Mr Mowrey      | 1                  | 1        | -                                                  | -        |

<sup>1</sup> Committee meetings are performed by the Board as a whole.

During the financial year, the Directors also met regularly on Company matters on an informal basis.

### ENVIRONMENTAL REGULATIONS

The Group's operations are not regulated by any significant environmental regulation under a law of the commonwealth or of a State or Territory of Australia.

### INDEMNIFYING OFFICER OR AUDITOR

No indemnities have been given or agreed to be given or insurance premiums paid or agreed to be paid, during or since the end of the financial year, to any person who is or has been an officer or auditor of the Company.

### PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied for leave of Court to bring proceedings on behalf of the Group or intervene in any proceedings to which the Group is party for the purpose of taking responsibility on behalf of the Group for all or any part of those proceedings. The Group was not a party to any proceedings during the year.

### NON-AUDIT SERVICES

There were no provisions of non-audit services to the Company during the financial year, by the auditor.

### AUDITOR'S INDEPENDENCE DECLARATION

A copy of the Auditor's Independence Declaration as required under section 307C of the Corporations Act 2001 has been included.

Signed in accordance with a resolution of the Board of Directors.



**Theresa Smits**

Chairperson

Perth WA

Date: 30 September 2026

---

**Grant Thornton Audit Pty Ltd**  
Level 43 Central Park  
152-158 St Georges Terrace  
Perth WA 6000  
PO Box 7757  
Cloisters Square  
Perth WA 6850  
T +61 8 9480 2000

## Auditor's Independence Declaration

### To the Directors of ClearVue Technologies Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the audit of ClearVue Technologies Limited for the year ended 30 June 2026, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- b no contraventions of any applicable code of professional conduct in relation to the audit.

Grant Thornton

Grant Thornton Audit Pty Ltd  
Chartered Accountants



B E Burgess  
Partner – Audit & Assurance

Perth, 30 September 2026

---

[grantthornton.com.au](http://grantthornton.com.au)

ACN-130 913 594

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

# CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED 30 JUNE 2026

|                                       | NOTE | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|---------------------------------------|------|-----------------------------------|-----------------------------------|
| Revenue from contracts with customers |      | 108,484                           | 249,925                           |
| Other income                          | 15   | 977,289                           | 910,041                           |
|                                       |      | <b>1,085,773</b>                  | <b>1,159,966</b>                  |

| EXPENSES                              |    |                     |                     |
|---------------------------------------|----|---------------------|---------------------|
| Consulting expense                    |    | (2,493,808)         | (3,167,310)         |
| Employee benefits expense             |    | (2,703,862)         | (3,281,565)         |
| Material costs                        |    | (565,998)           | (1,084,439)         |
| Product development testing           |    | (954,566)           | (364,186)           |
| Travel expenses                       |    | (568,064)           | (712,759)           |
| Legal fees                            |    | (493,144)           | (211,256)           |
| Finance costs                         | 16 | (83,073)            | (33,135)            |
| Depreciation and amortisation expense |    | (709,210)           | (524,998)           |
| Impairment                            | 8  | (2,535,408)         | (786,363)           |
| Share-based payments expense          | 19 | (199,320)           | (526,492)           |
| Other expenses                        | 17 | (1,641,237)         | (2,052,169)         |
|                                       |    | <b>(12,947,690)</b> | <b>(12,744,672)</b> |

| LOSS                                         |    |                     |                     |
|----------------------------------------------|----|---------------------|---------------------|
| Loss before income tax                       |    | (11,861,917)        | (11,584,706)        |
| Income tax expense                           | 27 | -                   | -                   |
| Loss for the year                            |    | (11,861,917)        | (11,584,706)        |
| Other comprehensive income / (loss)          |    | -                   | -                   |
| <b>Total comprehensive loss for the year</b> |    | <b>(11,861,917)</b> | <b>(11,584,706)</b> |

| LOSS PER SHARE ATTRIBUTABLE TO THE OWNERS OF THE COMPANY (CENTS) |    |       |       |
|------------------------------------------------------------------|----|-------|-------|
| Basic loss per share                                             | 28 | (4.0) | (4.5) |
| Diluted loss per share                                           | 28 | (4.0) | (4.5) |

See accompanying notes to the consolidated financial statements.

# CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2026

|                                          | NOTE | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|------------------------------------------|------|-----------------------------------|-----------------------------------|
| <strong>ASSETS</strong>                  |      |                                   |                                   |
| <strong>CURRENT ASSETS</strong>          |      |                                   |                                   |
| Cash and cash equivalents                | 3    | 4,420,700                         | 3,591,254                         |
| Trade and other receivables              | 4    | 905,953                           | 1,009,027                         |
| Other assets                             | 5    | 482,639                           | 711,476                           |
|                                          |      | <strong>5,809,292</strong>        | <strong>5,311,757</strong>        |
| <strong>NON-CURRENT ASSETS</strong>      |      |                                   |                                   |
| Plant and equipment                      | 6    | 429,169                           | 525,210                           |
| Right of use asset                       | 7    | 599,107                           | 472,517                           |
| Intangible assets                        | 8    | 3,581,093                         | 6,052,189                         |
| Other assets                             | 5    | 150,944                           | 144,496                           |
|                                          |      | <strong>4,760,313</strong>        | <strong>7,194,412</strong>        |
| <strong>Total Assets</strong>            |      | <strong>10,569,605</strong>       | <strong>12,506,169</strong>       |
| <strong>LIABILITIES</strong>             |      |                                   |                                   |
| <strong>CURRENT LIABILITIES</strong>     |      |                                   |                                   |
| Trade and other payables                 | 9    | 1,030,725                         | 1,765,343                         |
| Borrowings                               | 10   | 1,926,750                         | 409,158                           |
| Lease liabilities                        | 11   | 159,115                           | 80,664                            |
| Contract liabilities                     |      | 181,222                           | 246,614                           |
| Provisions                               | 12   | 120,330                           | 241,319                           |
|                                          |      | <strong>3,418,142</strong>        | <strong>2,743,098</strong>        |
| <strong>NON-CURRENT LIABILITIES</strong> |      |                                   |                                   |
| Lease liabilities                        | 11   | 480,081                           | 410,961                           |
| Provisions                               | 12   | 64,087                            | 101,875                           |
|                                          |      | <strong>544,168</strong>          | <strong>512,836</strong>          |
| <strong>Total Liabilities</strong>       |      | <strong>3,962,310</strong>        | <strong>3,255,934</strong>        |
| <strong>Net Assets</strong>              |      | <strong>6,607,295</strong>        | <strong>9,250,235</strong>        |
| <strong>EQUITY</strong>                  |      |                                   |                                   |
| Share capital                            | 13   | 60,838,400                        | 51,349,503                        |
| Share-based payments reserve             | 14   | 3,616,760                         | 8,624,453                         |
| Accumulated losses                       |      | (57,847,865)                      | (50,723,721)                      |
| <strong>Total Equity</strong>            |      | <strong>6,607,295</strong>        | <strong>9,250,235</strong>        |

See accompanying notes to the consolidated financial statements.

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

## FOR THE YEAR ENDED 30 JUNE 2026

|                                              | SHARE CAPITAL<br>\$ | SHARE-BASED<br>PAYMENTS<br>RESERVE<br>\$ | ACCUMULATED<br>LOSSES<br>\$ | TOTAL<br>\$         |
|----------------------------------------------|---------------------|------------------------------------------|-----------------------------|---------------------|
| Balance at 1 July 2024                       | 41,021,685          | 8,592,859                                | (39,545,637)                | 10,068,907          |
| Loss for the year                            | -                   | -                                        | (11,584,706)                | (11,584,706)        |
| Other comprehensive income                   | -                   | -                                        | -                           | -                   |
| <b>Total comprehensive loss for the year</b> | <b>-</b>            | <b>-</b>                                 | <b>(11,584,706)</b>         | <b>(11,584,706)</b> |
| Share based payments                         | 88,278              | 99,410                                   | -                           | 187,688             |
| Performance rights exercised                 | -                   | (134,863)                                | 134,863                     | -                   |
| Options issued                               | -                   | 338,806                                  | -                           | 338,806             |
| Options exercised                            | 3,392,900           | (195,596)                                | 195,596                     | 3,392,900           |
| Options expired                              | -                   | (76,163)                                 | 76,163                      | -                   |
| Ordinary shares issued                       | 7,500,000           | -                                        | -                           | 7,500,000           |
| Share issue costs                            | (653,360)           | -                                        | -                           | (653,360)           |
| <b>Balance at 30 June 2025</b>               | <b>51,349,503</b>   | <b>8,624,453</b>                         | <b>(50,723,721)</b>         | <b>9,250,235</b>    |
| Balance at 1 July 2025                       | 51,349,503          | 8,624,453                                | (50,723,721)                | 9,250,235           |
| Loss for the year                            | -                   | -                                        | (11,861,917)                | (11,861,917)        |
| Other comprehensive income                   | -                   | -                                        | -                           | -                   |
| <b>Total comprehensive loss for the year</b> | <b>-</b>            | <b>-</b>                                 | <b>(11,861,917)</b>         | <b>(11,861,917)</b> |
| Share based payments                         | 469,240             | -                                        | -                           | 469,240             |
| Performance rights issued                    | -                   | 254,015                                  | -                           | 254,015             |
| Performance rights forfeited                 | -                   | (4,320,000)                              | 4,320,000                   | -                   |
| Options issued                               | -                   | 305,477                                  | -                           | 305,477             |
| Options exercised                            | 309,700             | -                                        | -                           | 309,700             |
| Options expired                              | -                   | (1,247,185)                              | 417,773                     | (829,412)           |
| Ordinary shares issued                       | 9,460,365           | -                                        | -                           | 9,460,365           |
| Share issue costs                            | (750,408)           | -                                        | -                           | (750,408)           |
| <b>Balance at 30 June 2026</b>               | <b>60,838,400</b>   | <b>3,616,760</b>                         | <b>(57,847,865)</b>         | <b>6,607,295</b>    |

See accompanying notes to the consolidated financial statements.

# CONSOLIDATED STATEMENT OF CASH FLOW

FOR THE YEAR ENDED 30 JUNE 2026

|                                                             | NOTE | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------------------------------------------------------|------|-----------------------------------|-----------------------------------|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                 |      |                                   |                                   |
| Receipts from customers and others                          |      | 1,098,456                         | 1,369,251                         |
| Payments to suppliers, employees and others                 |      | (9,722,986)                       | (10,653,466)                      |
| Interest received                                           |      | 22,412                            | 52,342                            |
| Interest paid                                               |      | (83,073)                          | -                                 |
| <b>Net cash (used in) operating activities</b>              | 30   | <b>(8,685,191)</b>                | <b>(9,231,873)</b>                |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>                 |      |                                   |                                   |
| Payments for patents and trademarks                         |      | (596,212)                         | (1,241,998)                       |
| Purchase of plant and equipment                             |      | (25,089)                          | (62,436)                          |
| <b>Net cash (used in) investing activities</b>              |      | <b>(621,301)</b>                  | <b>(1,304,434)</b>                |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                 |      |                                   |                                   |
| Options exercised                                           |      | 309,000                           | 3,392,900                         |
| Ordinary shares issued                                      |      | 9,461,065                         | 7,500,000                         |
| Share issue costs                                           |      | (750,408)                         | (654,440)                         |
| Loan proceeds                                               |      | 2,024,334                         | 409,159                           |
| Loan repayments                                             |      | (806,743)                         | -                                 |
| Lease payments                                              |      | (79,840)                          | (75,395)                          |
| <b>Net cash from financing activities</b>                   |      | <b>10,157,408</b>                 | <b>10,572,224</b>                 |
| <b>Net Increase (decrease) in cash and cash equivalents</b> |      | <b>850,916</b>                    | <b>35,917</b>                     |
| <b>Effects of currency translation on cash</b>              |      | <b>(21,470)</b>                   | <b>852</b>                        |
| <b>Cash and cash equivalents at beginning of year</b>       |      | <b>3,591,254</b>                  | <b>3,554,485</b>                  |
| <b>Cash and cash equivalents at end of year</b>             | 3    | <b>4,420,700</b>                  | <b>3,591,254</b>                  |

See accompanying notes to the consolidated financial statements.

## FOR THE YEAR ENDED 30 JUNE 2026

These notes form an integral part of and should be read in conjunction with the accompanying financial report.

### 1. CORPORATE INFORMATION AND CONSOLIDATED STATEMENT OF COMPLIANCE

The consolidated financial report covers ClearVue Technologies Limited ("the Company") and its controlled entities ("the Group"). The Company is a Company limited by shares, incorporated and domiciled in Australia; whose shares are publicly traded on the Australian Securities Exchange. The address of its registered office and its principal place of business is Suite 9/567 Newcastle Street, West Perth, WA 6005, Australia.

The consolidated annual report for the year ended 30 June 2026 was authorised for issue, in accordance with a resolution of Directors, on 30 September 2026. The Directors have the power to amend and reissue the financial statements.

The consolidated annual report is a general-purpose financial report that has been prepared in accordance with the requirements of the Corporations Act 2001, Accounting Standards and other authoritative pronouncements of the Australian Accounting Standards Board. Compliance with the Australian Accounting Standards results in full compliance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

#### ***Nature of Operations***

The principal activities of the Group during the course of the year were research and development activities applied to the Company's world leading solar glass and BIPV technology.

### 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The following is a summary of the material accounting policies adopted by the economic entity in the preparation of the consolidated annual report. The accounting policies have been consistently applied, unless otherwise stated.

#### 2.1 Basis of Preparation

Except for cash flow information, the consolidated annual report is prepared on an accruals basis and is based on historical costs. The consolidated annual report has been prepared under the assumption that the Group operates on a going concern basis. The financial statements have been presented in Australian dollars (AUD), which is the Group's functional and presentation currency.

#### 2.2 Going Concern

The Group incurred an operating loss after income tax for the year ended 30 June 2026 of \$11,861,917 (\$11,584,706 loss for 2025) and reported net cash outflows from operating activities of \$8,685,191 (\$9,231,873 outflows for 2025) and investing activities of \$621,301 cash outflow (\$1,304,434 outflow for 2025). As at 30 June 2026, the Group had available cash and cash equivalents of \$4,420,700 (\$3,591,254 at 30 June 2025). The Company has the ability to defer or reduce its operating expenditure.

The Group has a \$30 million, 5-year At-Call Funding facility with Alpha Investment Partners to support growth plans and progress towards commercialisation. As at 30 June 2026 the Group had \$24 million At-Call Funding facility available.

On 21 July 2026 the Company completed a Share Purchase Plan receiving a total of \$1,291,000 for 14,670,426 ordinary shares with 1 for 1 free attaching options with a exercise price of \$0.115 expiring three years from their issue date.

The Company continues to pursue a range of potential funding initiatives, including, discussions with existing funding parties and applications for grant funding. These funding initiatives remain subject to further negotiation, and accordingly are not committed at the date of this financial report.

In assessing the appropriateness of the going concern assumption, the Directors have considered the Group's successful history of capital raising, including the available At-Call Funding facility and the ability to defer or reduce expenditure.

This financial report has been prepared on a going concern basis which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

#### 2.3 Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held on call with banks and other short-term highly liquid investments with original maturities of three months or less.

## 2.4 Plant and Equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

|                  |           |
|------------------|-----------|
| Furniture        | 10%-15%   |
| Office equipment | 28%-33.3% |
| Machinery        | 13%-15%   |

The carrying values of plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable. The residual value, useful life and depreciation method are reviewed at the end of each financial year to ensure that the amount, method and period of depreciation are consistent with previous estimates and the expected pattern of consumption of the future economic benefits embodied in the items of plant and equipment.

An item of plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognised.

## 2.5 Intangible Assets

### **Patents and Trademarks**

Patents and trademark costs are capitalised in the period in which they are incurred and amortised over their useful lives. Patents and trademarks are amortised over 20 years from the date of purchase.

### **Research and Development**

Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the consolidated entity is able to use or sell the asset; the consolidated entity has sufficient resources; and intent to complete the development and its costs can be measured reliably. Capitalised development costs are amortised over the period of their expected useful life, when the asset is determined available for use. The useful life, when available for use has been determined to be 10 years based on the expected viability of the product. In prior periods, the useful life was determined to be 20 years. Patents costs that relate to projects that are in the development phase are capitalised.

Research and development grants receivable are matched to their classification of expenditure. In the periods where research costs are expensed, the related research and development grant is reported in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as other income. In periods where the Group incurs development costs, the related research and development grant is recognised in the Consolidated Statement of Profit or Loss and Other Comprehensive Income.

The carrying value of development expenditure, intangible assets and intellectual property is tested for impairment annually when the asset is not yet available for use or more frequently when an indication of impairment arises during the reporting period.

## 2.6 Trade and Other Payables

These amounts include liabilities for goods and services provided to the entity prior to the end of the financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

## 2.7 Provisions

Provisions are recognised when the entity has a legal or constructive obligation resulting from past events, for which it is probable that there will be an outflow of economic benefits and that outflow can be reliably measured. Provisions are measured using the best estimate available of the amounts required to settle the obligation at the end of the reporting period.

## 2.8 Financial Instruments

### **Recognition, Initial Measurement and Derecognition**

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transaction costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below.

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred. A financial liability is derecognised when it is extinguished,

discharged, cancelled or expires.

### **Classification and Subsequent Measurement of Financial Assets**

Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with AASB 15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable).

For the purpose of subsequent measurement, financial asset other than those designated and effective as hedging instruments are classified into the following categories upon initial recognition:

- Amortised cost;
- Fair value through profit or loss (FVPL);
- Equity instruments at fair value through other comprehensive income (FVOCI); and
- Debt instruments at fair value through other comprehensive income (FVOCI).

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables, which are presented within other expenses.

Classifications are determined by both:

- The entities business model for managing the financial asset; and
- The contractual cash flow characteristics of the financial asset.

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables, which are presented within other expenses.

### **Financial Assets at Amortised Cost**

Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL):

- They are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows; and
- The contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding.

After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group's cash and cash equivalents, trade and most other receivables fall into this category of financial instruments.

There are no FVPL and FVOCI instruments for the group.

### **Impairment of Financial Assets**

AASB 9's impairment requirements use more forward-looking information to recognise expected credit losses – the 'expected credit losses (ECL) model'. Instruments within the scope of the new requirements included loans and other debt-type financial assets measured at amortised cost and FVOCI, trade receivables, contract assets recognised and measured under AASB 15 and loan commitments and some financial guarantee contract (for the issuer) that are not measured at fair value through profit or loss.

The Group considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument.

In applying this forward-looking approach, a distinction is made between:

- Financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk ('Stage 1'); and
- Financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low ('Stage 2').
- 'Stage 3' would cover financial assets that have objective evidence of impairment at the reporting date. '12-month expected credit losses' are recognised for the first category while 'lifetime expected credit losses' are recognised for the second category. Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument.

### **Trade and Other Receivables and Contract Assets**

The Group makes use of a simplified approach in accounting for trade and other receivables, as well as contract assets, and records the loss allowance at the amount equal to the expected lifetime credit losses. In using this practical expedient, the Group

uses its historical experience, external indicators and forward-looking information to calculate the expected credit losses using a provision matrix.

### **Classification and Measurement of Financial Liabilities**

The Group's financial liabilities include trade and other payables.

Financial liabilities are initially measured at fair value, and where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method except for derivatives and financial liabilities designated at FVPL, which are carried subsequently at fair value with gains or losses recognised in profit or loss (other than derivative financial instruments that are designated and effective as hedging instruments).

All interest-related charges and, if applicable, change in an instrument's fair value that are reported in profit or loss, are included within finance costs or finance income.

## **2.9 Impairment of Non-Financial Assets**

At each reporting date, the Directors review the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the assets fair value less costs to sell and value in use, is compared to the assets carrying value.

### **2.10 Impairment of Non-Financial Assets**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

### **2.11 Issued Capital**

Ordinary shares are classified as equity. Issued and paid up capital is recognised at the fair value of the consideration received by the Company. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction of the share proceeds received.

### **Basic Loss per Share**

Basic loss per share is determined by dividing the operating profit/(loss) after income tax attributable to members of ClearVue Technologies Limited by the weighted average number of ordinary shares outstanding during the financial year.

### **Diluted Loss per Share**

Diluted loss per share adjusts the amounts used in the determination of basic loss per share by taking into account unpaid amounts on ordinary shares and any reduction in loss per share that will probably arise from the exercise of options outstanding during the financial year.

## **2.12 Revenue and Other Income Recognition**

### **Revenue from Contracts with Customers**

The company has generated income from the sale of integrated glass unit windows. Revenue from the sale of the goods is recognised when based on the following 5 steps.

- A valid agreement is confirmed to exist;
- The performance obligations in the contract have been achieved;
- The transaction price has been determined;
- The transaction price can be allocated to the performance obligations;
- Revenue is recognised when a performance obligation is satisfied

**Grant Income**

Grant income is recognised in the income statement, when it is probable that the entity will receive the economic benefits of the grant and the amount can be reliably measured. If the grant has conditions attached which must be satisfied before the entity is eligible to receive the grant, the recognition of the income will be deferred until those conditions are satisfied.

Where the entity incurs an obligation to deliver economic value back to the grant contributor, the transaction is considered a reciprocal transaction and the income is recognised as a liability in the Consolidated Statement of financial position until the required service has been completed, otherwise the income is recognised on receipt.

Government grants are recognised when it is received or when the right to receive payment is established.

**Interest**

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

**Other Income**

Other revenue is recognised when the Group's right to receive the income is established and can be reliably measured.

**2.13 Employee Benefits****Short-Term Employee Benefits**

Short-term employee benefits are benefits, other than termination benefits, that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. Examples of such benefits include wages and salaries, non-monetary benefits and accumulating sick leave. Short-term employee benefits are measured at the undiscounted amounts expected to be paid when the liabilities are settled.

**Other Long-Term Employee Benefits**

The Group's liabilities for annual leave and long service leave are included in other long-term benefits as they are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are measured at the present value of the expected future payment to be made to employees. The expected future payments incorporate anticipated future wage and salary levels, experience of employee departures and periods of service, and are discounted at rates determined by reference to market yields at the end of the reporting period on high quality corporate bonds that have maturity dates that approximate the timing of the estimated future cash outflows. Any re-measurements arising from experience adjustments and changes in assumptions are recognised in profit or loss in the periods in which the changes occur.

**Defined Contribution Superannuation Expense**

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

**2.14 Share-Based Payments**

Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Binomial, Monte Carlo or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous

periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- During the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired option of the vesting period; and
- From the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

## 2.15 Income Tax

The charge for current income tax expenses is based on the profit for the year adjusted for any non-assessable or non-deductible items. It is calculated using tax rates that have been enacted or are substantively enacted by the end of each financial year.

Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. No deferred income tax will be recognised from the initial recognition of an asset or liability, excluding business combination, where there is no effect on accounting or taxable profit or loss.

Deferred tax is calculated at the tax rates that are expected to apply to the period when the asset is realised or liability is settled. Deferred tax is credited in profit and loss except where it relates to items that may be credited directly to equity, in which case the deferred tax is adjusted directly against equity.

Deferred income tax assets are recognised to the extent that it is probable that future tax profits will be available against which deductible temporary differences can be utilized.

The amount of benefits brought to account or which may be realised in the future is based on the assumption that no adverse change will occur in income tax legislation and the anticipation that the economic entity will derive sufficient future assessable income to enable the benefit to be realised and comply with the conditions of deductibility imposed by the law.

## 2.16 Goods and Services Tax (GST)

Transactions are recognised net of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office (ATO).

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the Consolidated Statement of financial position.

## 2.17 Critical Accounting Estimates and Judgements

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

### **Share Based Payments**

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity

instruments at the date at which they are granted. The fair value is determined by an external valuer using a Black-Scholes or Monte Carlo models, using the assumptions detailed in Note 14.

### ***Impairment of Intangible Assets***

Intangible assets are reviewed for impairment whenever there is an indication that these assets may be impaired. This includes any capitalised internally developed software that is not yet complete is not amortised. The Group consider the guidance of AASB 136 in assessing whether there is any indication that an item of the above assets may be impaired. This assessment requires management's judgement. If any such indication exists, the recoverable amount of the assets is estimated to ascertain the amount of impairment loss. The recoverable amount is defined as the higher of the fair value less cost to sell and value in use.

The Group reviews the appropriateness of the useful lives and residual values of intangible assets at the end of each reporting period. Changes in the expected level of usage and technological developments could impact the economic useful lives and residual values of these assets. Where there is a material change in the useful lives and residual values of intangible assets, such a change may impact the future amortisation charge in the financial year in which the change arises.

### ***Deferred Tax***

The Company expects to have carried forward tax losses which have not been recognised as deferred tax assets as it is not considered sufficiently probable that these losses will be recouped by means of future profits taxable in the relevant jurisdictions.

### ***Going Concern***

The Directors exercise significant judgement in assessing the Group's ability to continue as a going concern, based on cash flow forecasts covering at least 12 months from the date the financial report is authorised for issue. Key assumptions include forecast expenditure, the ability to defer or reduce costs, available committed funding and the timing of future funding. As future funding is not committed and actual cash flows may differ from forecast, the Group may need to further reduce expenditure or secure alternative funding.

### ***Capitalised Development Costs***

Distinguishing the research and development phases of the project and determining whether the recognition requirements phases of the project and determining whether the recognition requirements for the capitalisation of development costs are met requires judgement. After capitalisation, management monitors whether recognition requirements continue to be met and whether there are any indicators that capitalised costs may be impaired.

### ***Useful Life of Intangible Assets***

Management reviews its estimate of the useful lives of amortisable assets at each reporting date, based on the expected utility of the assets. During the period the consolidated entity's development asset was assessed as being ready for use. Once an asset is ready for use it is required to determine its expected useful life.

### ***R&D Tax Incentive***

The Group's research and development activities may be eligible under the Australian Government's Research and Development (R&D) Tax Incentive scheme. Management has assessed these activities and the related expenditure to determine which are likely to be eligible under the incentive scheme and the amount expected to be recovered.

## **2.18 Principles of Consolidation**

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of ClearVue Technologies Limited ('Company' or 'Group') as at 30 June 2026 and the results of all subsidiaries for the year then ended. The Group and its subsidiaries together are referred to in these financial statements as the 'consolidated entity'.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls and entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies

adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

## 2.19 Operating Segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Board of Directors. They are responsible for the allocation of resources to operating segments and assessing their performance.

## 2.20 Leases

The Group considers whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'. To apply this definition the Group assesses whether the contract meets three key evaluations which are whether:

- The contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Group.
- The Group has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract.
- The Group has the right to direct the use of the identified asset throughout the period of use. The Group assess whether it has the right to direct 'how and for what purpose' the asset is used throughout the period of use.

### **Measurement and Recognition of Leases**

At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received).

The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group's incremental borrowing rate.

Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.

Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments.

## 2.21 New or Amended Accounting Standards and Interpretations not yet Effective and not Early Adopted by the Group

At the date of authorisation of these financial statements, several new, but not yet effective, Standards and amendments to existing Standards, and Interpretations have been published by the AASB. None of these Standards or amendments to existing Standards have been adopted early by the Group.

Management anticipates that all relevant pronouncements will be adopted for the first period beginning on or after the effective date of the pronouncement. New Standards, amendments and Interpretations not adopted in the current year have not been disclosed as they are not expected to have a material impact on the Group's financial statement, with the exception of AASB18.

There are expected to be material impacts from AASB 18 Presentation and Disclosure in Financial Statements: AASB 18 replaces AASB 101 as the standard describing the primary financial statements and sets out requirements for the presentation and disclosure information in AASB-compliant financial statements. The amendments are effective for annual reporting periods beginning on or after 1 January 2027.

### 3. CASH AND CASH EQUIVALENTS

|              | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|--------------|-----------------------------------|-----------------------------------|
| Cash at bank | 4,420,700                         | 3,591,254                         |

### 4. TRADE AND OTHER RECEIVABLES

|                       | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-----------------------|-----------------------------------|-----------------------------------|
| Trade receivables     | 53,440                            | 140,740                           |
| R&D rebate receivable | 852,513                           | 868,287                           |
|                       | 905,953                           | 1,009,027                         |

### 5. OTHER ASSETS

|                             | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-----------------------------|-----------------------------------|-----------------------------------|
| <b>CURRENT</b>              |                                   |                                   |
| Goods and service tax (GST) | 82,512                            | 102,387                           |
| Prepayments                 | 153,828                           | 393,066                           |
| Inventory                   | 25,868                            | 25,868                            |
| Other                       | 220,431                           | 190,155                           |
|                             | 482,639                           | 711,476                           |
| <b>NON-CURRENT</b>          |                                   |                                   |
| Deposits                    | 150,944                           | 144,496                           |



## 6. PLANT AND EQUIPMENT

|                               | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------------------------|-----------------------------------|-----------------------------------|
| Cost                          | 789,434                           | 818,248                           |
| Less accumulated depreciation | (360,265)                         | (293,038)                         |
| Carrying amount               | 429,169                           | 525,210                           |

| COST                    |          |         |
|-------------------------|----------|---------|
| Balance at 1 July 2025  | 818,248  | 755,812 |
| Additions               | 25,089   | 62,436  |
| Disposals               | (53,903) | -       |
| Balance at 30 June 2026 | 789,434  | 818,248 |

| ACCUMULATED DEPRECIATION        |         |         |
|---------------------------------|---------|---------|
| Balance at 1 July 2025          | 293,038 | 234,618 |
| Depreciation for the year       | 76,491  | 58,420  |
| Disposals                       | (9,264) | -       |
| Balance at 30 June 2026         | 360,265 | 293,038 |
| Carrying amount at 30 June 2026 | 429,169 | 525,210 |

## 7. RIGHT-OF-USE ASSET

|                               | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------------------------|-----------------------------------|-----------------------------------|
| Cost                          | 794,430                           | 567,020                           |
| Less accumulated amortisation | (195,323)                         | (94,503)                          |
| Carrying amount               | 599,107                           | 472,517                           |

| COST                    |         |         |
|-------------------------|---------|---------|
| Balance at 1 July 2025  | 567,020 | 567,020 |
| Additions               | 227,410 | -       |
| Balance at 30 June 2026 | 794,430 | 567,020 |

| ACCUMULATED AMORTISATION        |         |         |
|---------------------------------|---------|---------|
| Balance at 1 July 2025          | 94,503  | -       |
| Depreciation for the period     | 100,820 | 94,503  |
| Balance at 30 June 2026         | 195,323 | 94,503  |
| Carrying amount at 30 June 2026 | 599,107 | 472,517 |

## 8. INTANGIBLE ASSETS

|                        | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|------------------------|-----------------------------------|-----------------------------------|
| Patents and trademarks | 1,473,740                         | 3,666,079                         |
| Development asset      | 2,107,353                         | 2,386,110                         |
|                        | <b>3,581,093</b>                  | <b>6,052,189</b>                  |

### PATENTS AND TRADEMARKS

|                               |                  |                  |
|-------------------------------|------------------|------------------|
| Cost                          | 6,142,709        | 5,546,497        |
| Less accumulated amortisation | (4,668,969)      | (1,880,418)      |
| <b>Carrying amount</b>        | <b>1,473,740</b> | <b>3,666,079</b> |

### COST

|                                |                  |                  |
|--------------------------------|------------------|------------------|
| Balance at 1 July 2025         | 5,546,497        | 4,304,500        |
| Additions <sup>1</sup>         | 596,212          | 1,241,997        |
| <b>Balance at 30 June 2026</b> | <b>6,142,709</b> | <b>5,546,497</b> |

### ACCUMULATED AMORTISATION AND IMPAIRMENT

|                                        |                  |                  |
|----------------------------------------|------------------|------------------|
| Balance at 1 July 2025                 | 1,880,418        | 861,391          |
| Amortisation for the year              | 253,143          | 232,664          |
| Impairment losses                      | 2,535,408        | 786,363          |
| <b>Balance at 30 June 2026</b>         | <b>4,668,969</b> | <b>1,880,418</b> |
| <b>Carrying amount at 30 June 2026</b> | <b>1,473,740</b> | <b>3,666,079</b> |

### DEVELOPMENT ASSET

|                               |                  |                  |
|-------------------------------|------------------|------------------|
| Cost                          | 2,787,573        | 2,787,573        |
| Less accumulated amortization | (680,220)        | (401,463)        |
| <b>Carrying amount</b>        | <b>2,107,353</b> | <b>2,386,110</b> |

### COST

|                                |                  |                  |
|--------------------------------|------------------|------------------|
| Balance at 1 July 2025         | 2,787,573        | 2,787,573        |
| Additions                      | –                | –                |
| <b>Balance at 30 June 2026</b> | <b>2,787,573</b> | <b>2,787,573</b> |

### ACCUMULATED AMORTISATION

|                                            |                  |                  |
|--------------------------------------------|------------------|------------------|
| Balance at 1 July 2025                     | 401,463          | 262,084          |
| Amortisation for the year                  | 278,757          | 139,379          |
| <b>Balance at 30 June 2026</b>             | <b>680,220</b>   | <b>401,463</b>   |
| <b>Carrying amount at 30 June 2026</b>     | <b>2,107,353</b> | <b>2,386,110</b> |
| <b>Net carrying amount at 30 June 2026</b> | <b>3,581,093</b> | <b>6,052,189</b> |

## 8. INTANGIBLE ASSETS (CONTINUED)

Total research and development expenditure incurred in the profit and loss for the year amounted to \$1,959,800 (2025: \$1,996,040).

Intangible assets are stated at cost. The useful life of these patents and trademarks is estimated to be 20 years

Management conducted a review of its patent portfolio held to determine whether each patent continued to have future commercial value and would be renewed. The assessment was performed on an individual patent basis and considered expected future economic benefits, commercialisation prospects and management's intention to maintain the relevant patent protections.

As a result, impairment losses of \$2,535,408 were recognised in respect of patents assessed as having no recoverable amount. The recoverable amount of these patents was determined to be nil. The carrying value of the remaining development assets and patents was reviewed and management concluded these assets continue to have expected future commercial value and contribute to future revenues.

No other impairment indicators have been identified in relation to any other intangible assets in the current period. There continues to be a strong pipeline of projects being actively managed by the Company.

During the current reporting period, the opening accumulated amortisation balances have been reclassified within intangible assets to ensure an appropriate allocation across relevant asset classes. The total accumulated amortisation remains unchanged. Comparative figures have been updated accordingly.

## 9. TRADE AND OTHER PAYABLES

|                | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|----------------|-----------------------------------|-----------------------------------|
| Trade payables | 591,584                           | 1,031,016                         |
| Other payables | 84,925                            | 419,709                           |
| Accruals       | 354,216                           | 314,618                           |
|                | <b>1,030,725</b>                  | <b>1,765,343</b>                  |

## 10. BORROWINGS

|                            | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|----------------------------|-----------------------------------|-----------------------------------|
| Riverfort funding facility | 1,900,000                         | -                                 |
| Accrued interest           | 26,750                            | -                                 |
|                            | <b>1,926,750</b>                  | <b>-</b>                          |

During the year, the Group entered into a structured funding arrangement with RiverFort Global Opportunities PCC Ltd.

Under the arrangement, the Group received funding advances totalling \$1.9 million. The facility bears interest at a fixed rate of 8% per annum, is secured over the Group's FY26 R&D Tax Incentive receivable and has a maturity of 12 months from each advance date.

The arrangement also requires the Group to issue options over ordinary shares to RiverFort in connection with each advance received. The number of options issued is determined by reference to the relevant advance amount and prevailing share price metrics at the date of advance. The options are exercisable over a 24-month period from grant. The Group has recognised the facility as a financial liability.

## 11. LEASE LIABILITIES

|             | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------|-----------------------------------|-----------------------------------|
| Current     | 159,115                           | 80,664                            |
| Non-Current | 480,081                           | 410,961                           |

The Group has leases for the office and photocopiers. These lease liabilities are secured by the related underlying assets.

Future minimum lease payments at 30 June 2026 were as follows:

|                   | WITHIN 1 YEAR<br>\$ | 1-5 YEARS<br>\$ | AFTER 5 YEARS<br>\$ | TOTAL<br>\$ |
|-------------------|---------------------|-----------------|---------------------|-------------|
| Lease payments    | 186,809             | 513,587         | –                   | 700,396     |
| Finance charges   | (27,694)            | (33,506)        | –                   | (61,200)    |
| Net present value | 159,115             | 480,081         | –                   | 639,196     |

*Lease payments not recognised as a liability.*

Certain variable lease payments are not permitted to be recognised as lease liabilities and are expensed as incurred. The expense relating to payments are not recognised as lease liability is as follows:

|                               | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------------------------|-----------------------------------|-----------------------------------|
| Depreciation expense (Note 7) | 100,820                           | 94,503                            |
| Interest expense              | 24,165                            | (33,135)                          |
| Variable lease payments       | 61,367                            | 51,462                            |

Variable lease payments are expensed on the basis that they are not recognised as a lease liability include excess use charges on office equipment. Variable payment terms are used for a variety of reasons, including minimizing costs for equipment with infrequent use. Variable lease payments are expensed in the period they are incurred.

## 12. PROVISIONS

|                              | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|------------------------------|-----------------------------------|-----------------------------------|
| <b>CURRENT</b>               |                                   |                                   |
| Annual leave provision       | 120,330                           | 241,319                           |
|                              | <b>120,330</b>                    | <b>241,319</b>                    |
| <b>NON-CURRENT</b>           |                                   |                                   |
| Long service leave provision | 64,087                            | 101,875                           |
|                              | <b>64,087</b>                     | <b>101,875</b>                    |

### 13. SHARE CAPITAL

|                                    | 30 JUN 2026 NO. OF<br>SHARES | 30 JUN 2025 NO. OF<br>SHARES | 30 JUN 2026<br>\$ | 30 JUN 2025<br>\$ |
|------------------------------------|------------------------------|------------------------------|-------------------|-------------------|
| <b>SHARE ISSUED AND FULLY PAID</b> |                              |                              |                   |                   |
| Balance at 1 July 2025             | 268,625,167                  | 242,658,474                  | 51,349,503        | 41,021,685        |
| Shares issued                      | 67,743,973                   | 23,437,500                   | 9,460,365         | 7,500,000         |
| Share based payments               | 2,966,040                    | 454,193                      | 469,240           | 88,278            |
| Options exercised                  | -                            | 1,575,000                    | -                 | 3,392,900         |
| ATM facility conversion            | -                            | -                            | 309,700           | -                 |
| Performance rights exercised       | -                            | 500,000                      | -                 | -                 |
| ATM Collateral                     | 10,000,000                   | -                            | -                 | -                 |
| Share issue costs                  | -                            | -                            | (750,408)         | (653,360)         |
| <b>Balance at 30 June 2026</b>     | <b>349,335,180</b>           | <b>268,625,167</b>           | <b>60,838,400</b> | <b>51,349,503</b> |

The share capital of the Company consists only of fully paid ordinary shares; the shares do not have a par value. All shares are equally eligible to receive dividends and the repayment of capital and represent one vote at the shareholders' meeting of the Company.

### 14. SHARE-BASED PAYMENTS RESERVE

|                              | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|------------------------------|-----------------------------------|-----------------------------------|
| Opening balance              | 8,624,453                         | 8,592,859                         |
| Performance Rights granted   | 254,016                           | -                                 |
| Options granted              | 305,476                           | 338,805                           |
| Options exercised            | -                                 | (195,596)                         |
| Options expired              | (627,185)                         | (76,162)                          |
| Share based payment          | -                                 | 99,410                            |
| Performance rights exercised | -                                 | (134,863)                         |
| Performance rights forfeited | (4,940,000)                       | -                                 |
|                              | <b>3,616,760</b>                  | <b>8,624,453</b>                  |

## 14. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

|                                          | NO. OF OPTIONS | NO. OF PERFORMANCE RIGHTS | \$        |
|------------------------------------------|----------------|---------------------------|-----------|
| MOVEMENTS IN SHARE BASED PAYMENT RESERVE |                |                           |           |
| Balance at 1 July 2024                   | 21,727,262     | 15,000,000                | 8,592,859 |
| Options granted                          | 1,150,000      | –                         | 338,805   |
| Options exercised                        | (1,575,000)    | –                         | (195,596) |
| Options expired                          | (1,550,000)    | –                         | (76,162)  |
| Options vested                           | –              | –                         | 99,410    |
| Performance rights exercised             | –              | (500,000)                 | (134,863) |
| Balance at 30 June 2025                  | 19,752,262     | 14,500,000                | 8,624,453 |

|                                          | NO. OF OPTIONS | NO. OF PERFORMANCE RIGHTS | \$          |
|------------------------------------------|----------------|---------------------------|-------------|
| MOVEMENTS IN SHARE BASED PAYMENT RESERVE |                |                           |             |
| Balance at 1 July 2025                   | 19,752,262     | 14,500,000                | 8,624,453   |
| Options granted                          | 30,679,175     | –                         | 305,476     |
| Options exercised                        | –              | –                         | –           |
| Options expired                          | (11,102,262)   | –                         | (627,185)   |
| Performance rights issued                | –              | 3,000,000                 | 254,016     |
| Performance rights lapsed                | –              | (13,500,000)              | (4,940,000) |
| Balance at 30 June 2026                  | 39,329,175     | 4,000,000                 | 3,616,760   |

## 14. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

The following table illustrates the number and detail of share options on issue:

| CLASS              | NUMBER     | GRANT DATE | EXPIRY DATE | VESTING CONDITION                                                                                                                                              |
|--------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CPVAT              | 1,150,000  | 05/07/2024 | 30/06/2027  | No vesting conditions                                                                                                                                          |
| CPVAV              | 4,000,000  | 20/02/2026 | 20/02/2029  | No vesting conditions                                                                                                                                          |
| CPVAW              | 989,550    | 20/02/2026 | 20/02/2028  | No vesting conditions                                                                                                                                          |
| CPVAO <sup>3</sup> | 500,000    | 30/10/2023 | 30/10/2027  | Options vest on the condition the share price of the Company reaches \$0.50 and maintains a VWAP of \$0.50 for at least 14 days within and prior to the expiry |
| CPVAP <sup>2</sup> | 2,000,000  | 13/12/2023 | 13/12/2026  | No vesting conditions                                                                                                                                          |
| CPVAQ <sup>2</sup> | 2,000,000  | 13/12/2023 | 13/12/2026  | No vesting conditions                                                                                                                                          |
| CPVAU              | 25,689,625 | 20/02/2026 | 01/09/2026  | No vesting conditions                                                                                                                                          |
| CPVAM              | 3,000,000  | 20/06/2023 | 30/11/2026  | No vesting conditions                                                                                                                                          |

The following table illustrates the number and weighted average exercise prices of and movements in share options issued during the year:

|                                       | 2026              |                                    | 2025              |                                    |
|---------------------------------------|-------------------|------------------------------------|-------------------|------------------------------------|
|                                       | NUMBER            | WEIGHTED AVERAGE EXERCISE PRICE \$ | NUMBER            | WEIGHTED AVERAGE EXERCISE PRICE \$ |
| Outstanding at the beginning of year  | 19,752,262        | 0.56                               | 21,727,262        | 0.52                               |
| Granted during the year               | 30,679,175        | 0.22                               | 1,150,000         | 0.55                               |
| Exercised during the year             | -                 | -                                  | (1,575,000)       | 0.21                               |
| Expired during the year               | (11,102,262)      | 0.54                               | (1,550,000)       | 0.30                               |
| <b>Outstanding at the end of year</b> | <b>39,329,175</b> | <b>0.30</b>                        | <b>19,752,262</b> | <b>0.56</b>                        |
| <b>Exercisable at the end of year</b> | <b>39,239,175</b> | <b>0.30</b>                        | <b>12,752,262</b> | <b>0.58</b>                        |

## 14. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

The fair value of the equity-settled share options listed below is estimated as at the date of grant using the Black-Scholes and Monte Carlo models taking into account the terms and conditions upon which the options were granted.

|                                 | CPVAV         | CPVAL         | CPVAM         | CPVAO       | CPVAP         | CPVAQ         | CPVAT         |
|---------------------------------|---------------|---------------|---------------|-------------|---------------|---------------|---------------|
| Dividend yield (%)              | –             | –             | –             | –           | –             | –             | –             |
| Expected volatility (%)         | 85.00         | 85.00         | 93.39         | 90.00       | 93.39         | 93.39         | 80.00         |
| Risk-free interest rate (%)     | 3.83          | 3.83          | 5.0           | 4.0         | 5.0           | 5.0           | 3.97          |
| Expected life of option (years) | 3.0           | 2.0           | 2.45          | 4           | 3             | 3             | 3             |
| Exercise price (cents)          | 30            | 27            | 40            | 0           | 50            | 100           | 55            |
| Grant date share price (cents)  | 12            | 12            | 17            | 31          | 47.5          | 47.5          | 54            |
| Number of options               | 4,000,000     | 989,550       | 3,000,000     | 500,000     | 2,000,000     | 2,000,000     | 1,150,000     |
| Model used                      | Black Scholes | Black Scholes | Black Scholes | Monte Carlo | Black Scholes | Black Scholes | Black Scholes |

The expected life of the options based on historical data is not necessarily indicative of exercise patterns that may occur.

The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. No other features of options granted were incorporated into the measurement of fair value.



## 14. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

The conversion of the performance rights is dependent on the following:

### a. Class D Performance Rights

- i. In the event that the participant assisting the company completes the development and testing of vision and spandrel glass to achieve an A2 SO D1 fire rating confirmed by an independent third party testing, with such testing party approved by the company and certified to the EN13501.1 standard before the expiry date, each Class D Performance Right will vest and be convertible into a Share.

### b. Class K Performance Rights

- i. In the event the 15 day volume weighted average price of the Company's shares traded on the Australian Securities Exchange being at least \$0.30, each Class K Tranche A Performance Right will vest and be convertible into a Share.
- ii. In the event the 15 day volume weighted average price of the Company's shares traded on the Australian Securities Exchange being at least \$0.40, each Class K Tranche B Performance Right will vest and be convertible into a Share.
- iii. In the event the 15 day volume weighted average price of the Company's shares traded on the Australian Securities Exchange being at least \$0.60, each Class K Tranche C Performance Right will vest and be convertible into a Share.
- iv. In the event the 15 day volume weighted average price of the Company's shares traded on the Australian Securities Exchange being at least \$0.75, each Class K Tranche D Performance Right will vest and be convertible into a Share.

The fair value of the performance rights issued during the year is estimated as at the date of grant using the Black-Scholes and Monte Carlo models taking into account the terms and conditions upon which the rights were granted.

|                                 | CLASS D          | CLASS K<br>Tranche A | CLASS K<br>Tranche B | CLASS K<br>Tranche C | CLASS K<br>Tranche D |
|---------------------------------|------------------|----------------------|----------------------|----------------------|----------------------|
| Method                          | Black<br>Scholes | Monte<br>Carlo       | Monte<br>Carlo       | Monte<br>Carlo       | Monte<br>Carlo       |
| Grant date                      | 21/9/23          | 28/11/25             | 28/11/25             | 28/11/25             | 28/11/25             |
| Expiry date                     | 30/10/27         | 29/12/28             | 29/12/28             | 29/12/28             | 29/12/28             |
| Grant date share price (cents)  | 33.5             | 15.5                 | 15.5                 | 15.5                 | 15.5                 |
| Risk free interest rate (%)     | 4                | 3.8                  | 3.8                  | 3.8                  | 3.8                  |
| Volatility (%)                  | 90               | 80                   | 80                   | 80                   | 80                   |
| Fair value per security (cents) | 33.5             | 12.43                | 9.84                 | 7.59                 | 6.08                 |
| Number of Performance Rights    | 1,000,000        | 600,000              | 600,000              | 700,000              | 1,100,000            |

## 15. OTHER INCOME

|                                     | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------------------------------|-----------------------------------|-----------------------------------|
| Government grants                   | 36,600                            | -                                 |
| Research and development tax rebate | 865,497                           | 857,696                           |
| Interest received                   | 22,412                            | 52,345                            |
| Cost recovery - Landvac             | 52,780                            | -                                 |
|                                     | <b>977,289</b>                    | <b>910,041</b>                    |

Government grants received from the Department of Industry, Innovation and Science in relation to the Commercial Research Centre.

## 16. FINANCE COSTS

|                   | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------------|-----------------------------------|-----------------------------------|
| Interest expenses | 83,073                            | 33,135                            |

## 17. OTHER EXPENSES

|                           | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|---------------------------|-----------------------------------|-----------------------------------|
| Advertising and promotion | 398,098                           | 847,869                           |
| Freight and Courier fees  | 101,878                           | 228,025                           |
| Insurance expense         | 219,191                           | 286,331                           |
| Listing fees              | 158,900                           | 189,100                           |
| Office expenses           | 177,623                           | 157,662                           |
| Rental expenses           | 120,766                           | 161,828                           |
| Borrowing expenses        | 93,500                            | -                                 |
| General expense           | 371,281                           | 181,354                           |
|                           | 1,641,237                         | 2,052,169                         |

## 18. AUDITOR'S REMUNERATION

|                                                                         | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-------------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Audit / review of the financial report by Grant Thornton Audit Pty Ltd. | 145,203                           | 120,941                           |

## 19. SHARE-BASED PAYMENTS EXPENSE

|                                        | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|----------------------------------------|-----------------------------------|-----------------------------------|
| Shares issued to consultants           | 428,800                           | 88,278                            |
| Options issued to consultants          | 305,476                           | -                                 |
| Performance rights issued              | 254,016                           | -                                 |
| Shares issued in lieu of director fees | 40,440                            | -                                 |
| Options issued to employees            | -                                 | 438,214                           |
| Options forfeited                      | (209,412)                         | -                                 |
| Performance rights forfeited           | (620,000)                         | -                                 |
|                                        | 199,320                           | 526,492                           |

## 20. RELATED PARTY TRANSACTIONS

### Key Management Personnel

The aggregate compensation made to directors and key management personnel of the Group is set out below.

|                                      | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|--------------------------------------|-----------------------------------|-----------------------------------|
| Short-term employee benefits         | 2,130,360                         | 2,625,788                         |
| Post-employment benefits             | 138,208                           | 172,926                           |
| Share-based payments                 | 294,456                           | 255,322                           |
| Directors fees from Theresa Smits    | 66,267                            | -                                 |
| Directors fees from Michael Pixley   | 55,000                            | -                                 |
| Directors fees from Liang Ji         | 38,167                            | -                                 |
| Directors fees from Andrew Lau       | 16,452                            | -                                 |
| Directors fees From Doug Hunt        | 50,000                            | -                                 |
| Directors fees from Gerd Hoenicke    | -                                 | 60,000                            |
| Directors fees from Charles Mowrey   | 1,774                             | 60,000                            |
| Directors fees From Victor Rosenberg | 31,666                            | 86,000                            |
| Directors fees from Jamie Lyford     | 5,000                             | 60,000                            |
|                                      | 2,827,350                         | 3,320,036                         |

### Transactions with Related Parties

During the financial year, the following payments were made to director-related entities:

|                                                                       | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-----------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Fees from SACCHS Pty Ltd for COO, CEO and Board services <sup>2</sup> | 518,749                           | -                                 |
| Fees from Nepix Pty Ltd for Board services <sup>3</sup>               | 55,000                            | -                                 |
| Consultancy services from Luminate Pty Ltd <sup>1</sup>               | 48,369                            | 208,920                           |

<sup>1</sup> Director-related entity of Mr Rosenberg consultancy services have been included in short term employee benefits in the remuneration report.

<sup>2</sup> A director related entity of Mr Hunt

<sup>3</sup> A director related entity of Mr Pixley

## 20. RELATED PARTY TRANSACTIONS (CONTINUED)

### *Receivable from and Payable to Related Parties*

All transactions were made on normal commercial terms and conditions and at market rates.

|                                                   | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|---------------------------------------------------|-----------------------------------|-----------------------------------|
| Share plan reserve to Mr V Rosenberg <sup>1</sup> | 150,000                           | 150,000                           |
| Share plan reserve to Mr I Rosenberg <sup>2</sup> | 18,750                            | 18,750                            |
| Share plan reserve to Mr Lyford <sup>3</sup>      | 292,500                           | 292,500                           |
| Accrual to Ms Theresa Smits                       | 66,267                            | -                                 |
| Accrual to Mr Andrew Lau                          | 16,452                            | -                                 |
| Accrual to Mr Liang Ji                            | 38,167                            | -                                 |
| Amount owing to Mr Doug Hunt                      | 3,771                             | -                                 |
| Amount owing from Mr Doug Hunt                    | 7,802                             | -                                 |
| Amount owing to Ms Serjana Sadeq                  | 33                                | -                                 |

1 For the purchase of 1,000,000 shares at an issue price of \$0.15

2 For the purchase of 125,000 shares at an issue price of \$0.15

3 For the purchase of 1,950,000 shares at an issue price of \$0.15

## 21. CONTINGENT ASSETS & LIABILITIES

There were no contingent assets or liabilities as at 30 June 2026 (2025: nil).

## 22. EVENTS SUBSEQUENT THE END OF THE REPORTING PERIOD

Professor Rebecca Yang was appointed to the Board of Directors on 16 July 2026.

On 21 July 2026 the Company completed a Share Purchase Plan receiving a total of \$1,291,000 for 14,670,426 ordinary shares with 1 for 1 free attaching options with a exercise price of \$.115 expiring three years from their issue date. The free attaching options will be issued at a later date following shareholder approval at an upcoming General Meeting.

On 13 July 2026 the company repaid Riverfort Global \$600,000 principal and \$24,329 interest.

## 23. DIVIDENDS

No dividend has been declared or paid out in the financial year ended 30 June 2026 (2025: nil). The Directors do not recommend the declaration of a dividend.

## 24. OPERATING SEGMENTS

Management has determined the operating segments based on reports reviewed by the Board of Directors for making strategic decisions. The Board of Directors monitors the business based on operational and geographic factors and have determined that there is only one relevant business segment being ClearVue Technologies Limited and its controlled entities. The Group is domiciled in Australia and most revenue and expenditure is generated from Australia, and all assets are located in Australia.

## 25. CONSOLIDATED ENTITY

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly-owned subsidiaries in accordance with the accounting policy in Note 2.

| NAME OF ENTITY                 | TYPE OF ENTITY | COUNTRY OF INCORPORATION | OWNERSHIP<br>30 JUNE 2026 | OWNERSHIP<br>30 JUNE 2025 |
|--------------------------------|----------------|--------------------------|---------------------------|---------------------------|
| ClearVue Technologies Limited  | Body Corporate | Australia                | N/A                       | N/A                       |
| ClearVue International Pty Ltd | Body Corporate | Australia                | 100%                      | 100%                      |
| ClearVue USA Inc               | Body Corporate | United States of America | 100%                      | 100%                      |
| ClearVue (Asia) Pte Ltd        | Body Corporate | Singapore                | 100%                      | 100%                      |
| ClearVue Europe BV             | Body Corporate | Netherlands              | 100%                      | 100%                      |
| ClearVue Europe Holdings BV    | Body Corporate | Netherlands              | 100%                      | 100%                      |
| Opticrop (Israel) Ltd          | Body Corporate | Israel                   | 100%                      | 100%                      |
| ClearVue Hong Kong             | Body Corporate | Hong Kong                | 100%                      | N/A                       |

## 26. PARENT ENTITY INFORMATION

|                                                                                | 30 JUN 2026<br>\$   | 30 JUN 2025<br>\$  |
|--------------------------------------------------------------------------------|---------------------|--------------------|
| <b>CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME</b> |                     |                    |
| Loss after income tax                                                          | (10,496,611)        | (8,198,857)        |
| Other comprehensive income                                                     | –                   | –                  |
| <b>Total comprehensive income</b>                                              | <b>(10,496,611)</b> | <b>(8,198,857)</b> |
| <b>CONSOLIDATED STATEMENT OF FINANCIAL POSITION</b>                            |                     |                    |
| Total current assets                                                           | 11,379,298          | 8,591,352          |
| Total assets                                                                   | 15,885,092          | 15,241,340         |
| Total current liabilities                                                      | 2,998,535           | 1,566,863          |
| Total liabilities                                                              | 3,542,703           | 2,079,699          |
| Share capital                                                                  | 60,838,400          | 51,349,503         |
| Share based payments reserve                                                   | 3,616,759           | 8,624,453          |
| Accumulated losses                                                             | (52,112,770)        | (46,812,314)       |
|                                                                                | <b>12,342,389</b>   | <b>13,161,641</b>  |

### Guarantees

The parent entity had no guarantees that were entered in relation to the debts of its subsidiaries.

### Contingent Liabilities

The parent entity had no contingent liabilities as at 30 June 2026 and 30 June 2025.

### Capital Commitments

The parent entity had no capital commitments as at 30 June 2026 and 30 June 2025.

### Significant Accounting Policies

The accounting policies for the parent entity are consistent with those of the consolidated entity, as disclosed in Note 2.

## 27. INCOME TAX

The prima facie tax expense on pre-tax accounting loss from operations reconciles to the income tax expense as follows:

|                                                     | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-----------------------------------------------------|-----------------------------------|-----------------------------------|
| Current tax expense                                 | –                                 | –                                 |
| Deferred tax expense                                | –                                 | –                                 |
| Income tax expense                                  | –                                 | –                                 |
| Accounting profit/(loss)                            | (11,861,917)                      | (11,584,706)                      |
| Tax at statutory rate of 25%                        | (2,965,479)                       | (2,896,176)                       |
| Non-deductible expenditure                          | 58,802                            | 181,217                           |
| Non-assessable income                               | (216,374)                         | (214,424)                         |
| Temporary timing difference and loss not recognised | 2,633,102                         | 2,467,569                         |
| Tax gains not brought to account as DTL             | –                                 | –                                 |
| Refundable research expenditure                     | 489,950                           | 499,010                           |
| Income tax expense                                  | –                                 | –                                 |

### DEFERRED TAX ASSETS NOT BROUGHT TO ACCOUNT

|                                                         |                  |                  |
|---------------------------------------------------------|------------------|------------------|
| Trade and other payables                                | 11,691           | 12,472           |
| Accruals                                                | 88,554           | 78,655           |
| Employee benefits                                       | 46,104           | 85,798           |
| Tax losses from previous periods                        | 7,195,240        | 5,591,812        |
| <b>Total deferred tax assets not brought to account</b> | <b>7,341,589</b> | <b>5,768,737</b> |

### DEFERRED TAX LIABILITIES NOT BROUGHT TO ACCOUNT

|              |          |          |
|--------------|----------|----------|
| NA           | –        | –        |
| <b>Total</b> | <b>–</b> | <b>–</b> |

As of 30 June 2026, there was \$28,780,961 tax losses carried forward (2025: \$22,367,247) in the Australian entities.

1. The Company derives future assessable income of a nature and an amount sufficient to enable the benefit from the tax losses to be realised.
2. The Company continues to comply with the conditions for deductibility imposed by tax legislation.
3. No changes in tax legislation adversely affect the Company realising the benefit from the deduction of tax losses.

## 28. LOSS PER SHARE

|                                                                                                     | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-----------------------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Loss after income tax used in calculating basic and diluted earnings per share                      | (11,861,917)                      | (11,584,706)                      |
|                                                                                                     | NO.                               | NO.                               |
| Weighted average number of ordinary shares used in calculating basic and diluted earnings per share | 298,203,581                       | 259,491,780                       |
|                                                                                                     | CENTS                             | CENTS                             |
| Basic loss per share                                                                                | (4.0)                             | (4.5)                             |
| Diluted loss per share                                                                              | (4.0)                             | (4.5)                             |

As the Group incurred a loss for the period, the options on issue have an anti-dilutive effect, therefore the diluted EPS is equal to the basic EPS. A total of 43,710,256 share options which could potentially dilute EPS in the future have been excluded from the dilute EPS calculation because they are anti-dilutive for the current period.

## 29. FINANCIAL INSTRUMENTS

### Financial Risk Management Objectives

The Company's principal financial instruments comprise cash, receivables, payables, borrowings, leases and related party loans.

Primary responsibility for identification and control of financial risks rests with the Board. The Board reviews and agrees policies for managing each of the risks identified.

The Company manages its exposure to key financial risks, including interest rate, credit and liquidity risks in accordance with the Company's risk management policy. The primary objective of the policy is to reduce the volatility of cash flows and asset values arising from such movements.

The Company uses different methods to measure and manage the different types of risks to which it is exposed. These include monitoring the levels of exposure to interest rate risk, ageing analysis and monitoring of credit allowances to manage credit risk and the use of future cash flow forecasts to monitor liquidity risk.

### Credit Risk

The carrying amount of the Company's financial assets represents the maximum credit exposure. The Company's maximum exposure to credit risk at the reporting date was:

|                             | CONSOLIDATED<br>30 JUN 2026<br>\$ | CONSOLIDATED<br>30 JUN 2025<br>\$ |
|-----------------------------|-----------------------------------|-----------------------------------|
| Cash and cash equivalents   | 4,420,700                         | 3,591,254                         |
| Trade and other receivables | 905,953                           | 1,009,027                         |
|                             | 5,326,653                         | 4,600,281                         |

## 29. FINANCIAL INSTRUMENTS (CONTINUED)

The Company's maximum exposure to interest rates at the reporting date was:

|                                        |                                      | INTEREST RATE EXPOSURE |                           |                         |                           |           |
|----------------------------------------|--------------------------------------|------------------------|---------------------------|-------------------------|---------------------------|-----------|
|                                        | RANGE OF EFFECTIVE INTEREST RATE (%) | CARRYING AMOUNT \$     | VARIABLE INTEREST RATE \$ | NON-INTEREST BEARING \$ | FLOATING INTEREST RATE \$ | TOTAL \$  |
| <b>2026 FINANCIAL ASSETS – CURRENT</b> |                                      |                        |                           |                         |                           |           |
| Cash and cash equivalents              | 0.36                                 | 4,420,700              | 4,420,700                 | –                       | –                         | 4,420,700 |
| <b>2025 FINANCIAL ASSETS – CURRENT</b> |                                      |                        |                           |                         |                           |           |
| Cash and cash equivalents              | 0.36                                 | 3,591,254              | 3,591,254                 | –                       | –                         | 3,591,254 |

The Company's maximum exposure to credit risk for trade and other receivables at the reporting date was:

|                                        |                    | PAST DUE BUT NOT IMPAIRED        |               |                    |              |                              |
|----------------------------------------|--------------------|----------------------------------|---------------|--------------------|--------------|------------------------------|
|                                        | CARRYING AMOUNT \$ | NOT PAST DUE AND NOT IMPAIRED \$ | 1-3 MONTHS \$ | 3 MONTHS-1 YEAR \$ | 1-5 YEARS \$ | IMPAIRED FINANCIAL ASSETS \$ |
| <b>2026 FINANCIAL ASSETS – CURRENT</b> |                    |                                  |               |                    |              |                              |
| Cash and cash equivalents              | 4,420,700          | 4,420,700                        | 4,420,700     | –                  | –            | –                            |
| Trade and other receivables            | 905,953            | 905,953                          | 905,953       | –                  | –            | –                            |
|                                        | 5,326,653          | 5,326,653                        | 5,326,653     | –                  | –            | –                            |
| <b>2025 FINANCIAL ASSETS – CURRENT</b> |                    |                                  |               |                    |              |                              |
| Cash and cash equivalents              | 3,591,254          | 3,591,254                        | 3,591,254     | –                  | –            | –                            |
| Trade and other receivables            | 1,009,027          | 1,009,027                        | 1,009,027     | –                  | –            | –                            |
|                                        | 4,600,281          | 4,600,281                        | 4,600,281     | –                  | –            | –                            |

## 29. FINANCIAL INSTRUMENTS (CONTINUED)

### Liquidity Risk

The carrying amount of the Company's financial liabilities represents the maximum liquidity risk. The Company's maximum liquidity risk exposure to liquidity risk at the reporting date was:

|                              | CONSOLIDATED 30<br>JUN 2026<br>\$ | CONSOLIDATED 30<br>JUN 2025<br>\$ |
|------------------------------|-----------------------------------|-----------------------------------|
| Lease Liability              | 639,195                           | 491,625                           |
| Trade and other payables     | 1,222,371                         | 1,441,725                         |
| Borrowings                   | 1,926,750                         | 409,159                           |
| <b>Financial Liabilities</b> | <b>3,788,316</b>                  | <b>2,342,509</b>                  |

The following table discloses the contractual maturity analysis at the reporting date:

|                                             | CARRYING<br>AMOUNT<br>\$ | LESS THAN 1<br>MONTH<br>\$ | 1-3 MONTHS<br>\$ | 3 MONTHS-<br>1 YEAR<br>\$ | 1-5 YEARS<br>\$ | OVER 5 YEARS<br>\$ |
|---------------------------------------------|--------------------------|----------------------------|------------------|---------------------------|-----------------|--------------------|
| <b>2026 FINANCIAL LIABILITIES</b>           |                          |                            |                  |                           |                 |                    |
| Trade and other payables                    | 1,222,371                | 844,872                    | 57,010           | 320,489                   | -               | -                  |
| Lease liability                             | 639,195                  | 7,235                      | 40,162           | 151,680                   | 440,120         | -                  |
| Borrowings                                  | 1,926,750                | 624,329                    | -                | 1,302,421                 | -               | -                  |
| <b>2025 FINANCIAL LIABILITIES - CURRENT</b> |                          |                            |                  |                           |                 |                    |
| Trade and other payables                    | 1,441,725                | 645,709                    | 796,016          | 409,159                   | -               | -                  |
| Lease liability                             | 491,625                  | 6,565                      | 19,865           | 54,234                    | 410,961         | -                  |
| Borrowings                                  | 409,159                  | -                          | -                | 409,159                   | -               | -                  |

### Market Risk

The Company is not materially exposed to any foreign currency risk or other price risk at the report date. The Company's only exposure to interest rate risk is cash as disclosed below.

### Sensitivity Disclosure Analysis

Taking into account past performance, future expectations and economic forecasts, the Company believes the following movements are 'reasonably possible' over the next 12 months (base rates are sourced from the Reserve Bank of Australia).

It is considered that 50 basis points is a 'reasonably possible' estimate of potential variations in the interest rate.

The following table discloses the impact on net operating result and equity for each category of financial instrument held by the Company at year end as presented to key management personnel, if changes in the relevant risk occur.

## 29. FINANCIAL INSTRUMENTS (CONTINUED)

|                                        | CARRYING<br>AMOUNT<br>\$ | INTEREST RATE RISK |              |              |              |
|----------------------------------------|--------------------------|--------------------|--------------|--------------|--------------|
|                                        |                          | +0.5%              |              | -0.5%        |              |
|                                        |                          | PROFIT<br>\$       | EQUITY<br>\$ | PROFIT<br>\$ | EQUITY<br>\$ |
| <b>2026 FINANCIAL ASSETS – CURRENT</b> |                          |                    |              |              |              |
| Cash and cash equivalents              | 4,420,700                | 22,103             | 22,103       | (22,103)     | (22,103)     |
| <b>2025 FINANCIAL ASSETS – CURRENT</b> |                          |                    |              |              |              |
| Cash and cash equivalents              | 3,591,254                | 17,956             | 17,956       | (17,956)     | (17,956)     |

## 30. CASH FLOW INFORMATION

|                                                                                           | 30 JUN 2026<br>\$  | 30 JUN 2025<br>\$  |
|-------------------------------------------------------------------------------------------|--------------------|--------------------|
| <b>RECONCILIATION OF NET PROFIT AFTER TAX TO NET CASH FLOWS FROM OPERATING ACTIVITIES</b> |                    |                    |
| Loss before income tax                                                                    | (11,861,917)       | (11,584,706)       |
| <b>ADJUSTMENT FOR:</b>                                                                    |                    |                    |
| Effects of currency translation on cash                                                   | 21,470             | (854)              |
| Depreciation of plant and equipment                                                       | 177,309            | 152,957            |
| Amortisation of intangible assets                                                         | 3,067,308          | 1,158,407          |
| Loss on disposal of fixed assets                                                          | 44,639             | -                  |
| Share based payments                                                                      | 199,320            | 526,492            |
| <b>Operating loss before working capital</b>                                              | <b>(8,351,871)</b> | <b>(9,747,704)</b> |
| <b>CHANGES IN WORKING CAPITAL:</b>                                                        |                    |                    |
| Decrease/(Increase) in trade receivables                                                  | 103,077            | 135,814            |
| Decrease/(Increase) in other assets                                                       | 222,389            | (257,421)          |
| (Decrease)/Increase in trade and other payables                                           | (500,009)          | 535,637            |
| (Decrease)/Increase in provisions                                                         | (158,777)          | 101,801            |
| <b>Net cash (used in) operating activities</b>                                            | <b>(8,685,191)</b> | <b>(9,231,873)</b> |

## CONSOLIDATED ENTITY DISCLOSURE STATEMENT

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly-owned subsidiaries in accordance with the accounting policy in Note 2.

| NAME OF ENTITY                 | TYPE OF ENTITY | TRUSTEE PARTNER OR PARTICIPANT IN JOINT VENTURE | COUNTRY OF INCORPORATION | AUSTRALIAN RESIDENT OR FOREIGN ENTITY (FOR TAX PURPOSE) | FOREIGN TAX JURISDICTION FOR FOREIGN RESIDENTS | OWNERSHIP 30 JUNE 2026 |
|--------------------------------|----------------|-------------------------------------------------|--------------------------|---------------------------------------------------------|------------------------------------------------|------------------------|
| ClearVue Technologies Limited  | Body Corporate | NA                                              | Australia                | Australia                                               | NA                                             | NA                     |
| Opticrop (Israel) Limited      | Body Corporate | NA                                              | Israel                   | Foreign                                                 | Israel                                         | 100%                   |
| ClearVue International Pty Ltd | Body Corporate | NA                                              | Australia                | Australia                                               | NA                                             | 100%                   |
| ClearVue USA Inc               | Body Corporate | NA                                              | United States of America | Foreign                                                 | United States of America                       | 100%                   |
| ClearVue (Asia) Pte Ltd        | Body Corporate | NA                                              | Singapore                | Foreign                                                 | Singapore                                      | 100%                   |
| ClearVue Europe BV             | Body Corporate | NA                                              | Netherlands              | Foreign                                                 | Netherlands                                    | 100%                   |
| ClearVue Europe Holdings BV    | Body Corporate | NA                                              | Netherlands              | Foreign                                                 | Netherlands                                    | 100%                   |
| ClearVue Hong Kong Limited     | Body Corporate | NA                                              | Hong Kong                | Foreign                                                 | Hong Kong                                      | 100%                   |

### ***Basis of Preparation***

This Consolidated Entity Disclosure Statement (CEDS) has been prepared in accordance with the Corporations Act 2001 and includes the required information for each entity that was part of the consolidated entity as at the end of the financial year.

### ***Consolidated Entity***

This CEDS includes only those entities consolidated as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements (AASB 10).

### ***Determination of Tax Residency***

Section 295 (3A) of the Corporations Act 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as there are currently several different interpretations that could be adopted, and which could give rise to a different conclusion on residency.

In determining tax residency, the consolidated entity has applied the following interpretations:

### ***Australian Tax Residency***

The consolidated entity has applied current legislation and judicial precedent, including having regard to the Tax Commissioner's public guidance in Tax Ruling TR 2018/5 Income Tax: Central management and control test of residency.

1. In the opinion of the Directors of ClearVue Technologies Limited:
  - a. the consolidated financial report and notes are in accordance with the Corporations Act 2001, including:
    - i) giving a true and fair view of its financial position as at 30 June 2026 and of its performance for the period from 1 July 2025 to 30 June 2026; and
    - ii) complying with Australian Accounting Standards (including the Australian Interpretations) and the Corporations Regulations 2001; and
  - b. the consolidated entity disclosure statement on page 69 is true and correct as at 30 June 2026; and
  - c. at the date of this declaration, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.
2. The financial report complies with International Financial Reporting Standards (IFRS) as described in Note 2.

The Directors have been given the declarations required by section 295A of the Corporations Act 2001.

The declaration is made in accordance with a resolution of the Board of Directors required by section 295(5)(a) of the Corporations Act 2001.



Theresa Smits

Perth WA

Date: 30 September 2026

# Independent Auditor's Report

## To the Members of ClearVue Technologies Limited

### Report on the audit of the financial report

#### Opinion

We have audited the financial report of ClearVue Technologies Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- a giving a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the year ended on that date; and
- b complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

#### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

---

[grantthornton.com.au](http://grantthornton.com.au)

ACN-130 913 594

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

## Key audit matter

## How our audit addressed the key audit matter

### Capitalised intangible assets – Note 2.5 and Note 8

As at 30 June 2026, the Group held patents and trademarks with a carrying value of \$1,437,739 and a development asset of \$2,107,353, representing 34% of total assets. During the year, the Group capitalised \$596,212 of expenditure in relation to patents and trademarks. The Group also recognised an impairment expense of \$2,535,408 during the year against patents and trademarks where the Group either determined they were no longer being renewed or were not deemed viable.

AASB 138 *Intangible Assets* requires expenditure to meet specific recognition criteria in order to be capitalised. In addition, AASB 136 *Impairment of Assets* requires management to assess whether indicators of impairment exist and, where necessary, estimate the recoverable amount of assets.

Significant management judgement was required in:

- determining whether expenditure met the criteria for capitalisation;
- assessing the useful lives of capitalised intangible assets;
- assessing the capitalised intangible assets for indicators of impairment; and
- estimating the recoverable amounts of capitalised intangible assets for which impairment indicators were identified.

This is a key audit matter due to the significance of the Group's intangible asset balances and the impairment expense recognised during the year, and the significant judgement required in assessing capitalisation and impairment under AASB 138 and AASB 136. These matters required significant auditor attention and audit effort in evaluating management's judgements and assumptions.

Our procedures included:

- assessing the Group's capitalisation policy against the recognition requirements of AASB 138;
- evaluating management's assessment that projects met the recognition criteria set out in AASB 138 by inspecting patent lists and R&D project documentation to understand the nature and feasibility of projects, corroborated by inquiry with management;
- for a sample of items of expenditure capitalised, agreeing to underlying employment contracts and supplier invoices and assessing whether the expenditure was directly attributable to the development of the relevant asset and eligible for capitalisation under AASB 138;
- assessing the reasonableness of the useful lives assigned to patents and trademarks and evaluating the resulting amortisation expense; and
- obtaining an understanding of management's process for identifying indicators of impairment and determining the recoverable amount of intangible assets;
- evaluating management's assessment of impairment indicators, and where indicators were identified, evaluating management's assessment that assets were fully impaired by examining the patent register and forecast expenditure to identify expired patents projects for which no future activity was planned; and
- evaluating related disclosures against the requirements of Australian Accounting Standards.

### Research and development tax incentives – Note 4 and Note 15

The Group recognised a receivable and related income in respect of its expected entitlement under the Australian Research and Development (R&D) Tax Incentive scheme.

Determining the amount to be recognised requires significant judgement in assessing whether activities undertaken meet the definition of eligible R&D activities, whether expenditure incurred satisfies the requirements of the relevant legislation, and estimating the amount expected to be recoverable from the Australian Taxation Office.

This is a key audit matter due to the significant auditor judgement involved in assessing management's determination of the eligibility of activities and expenditure under the R&D tax incentive legislation and estimating the refundable tax offset receivable.

Our procedures included:

- obtaining an understanding of management's processes for estimating the claim;
- with the assistance of our internal specialists;
  - assessing the expenditure methodology employed by management against the R&D tax offset rules; and
  - assessing the nature of the expenses against the eligibility criteria of the R&D tax incentive scheme to conclude whether the expenses included in the estimate meet the eligibility criteria;
- comparing the prior year R&D incentive receivable to the amount of cash received after lodgement to assess the historical accuracy of the estimate;

- selecting a sample of R&D expenditure and agreeing to supporting documentation to ensure appropriate classification, the validity of the claimed amount, and eligibility against the R&D tax incentive scheme criteria; and
- evaluating the related disclosures against the requirements of Australian Accounting Standards.

---

#### **Funding arrangement with RiverFort Global Opportunities PCC Ltd – Note 10**

---

During the year, the Group entered into a funding arrangement with RiverFort Global Opportunities PCC Ltd (the lender) comprising a secured loan facility. As part of the funding arrangement, the Group granted options to the lender.

The accounting for the arrangement required significant judgement in evaluating the contractual terms of the funding arrangement to determine the appropriate classification and measurement in accordance with AASB 132 *Financial Instruments: Presentation* and AASB 9 *Financial Instruments*.

This is a key audit matter due to the significant auditor judgement required in assessing management's determination of the appropriate classification and initial measurement of the financial instruments arising from the funding arrangement, together with the complexity involved in applying the requirements of AASB 132 and AASB 9.

Our procedures included:

- evaluating the classification and initial measurement of the funding arrangement and associated options by examining the executed funding agreements and option deed, assessing the economic substance of the significant terms and conditions, and assessing management's accounting treatment against the requirements of AASB 132 and AASB 9;
  - evaluating the appropriateness of the initial measurement and recognition of the debt and equity components of the arrangement;
  - testing the mathematical accuracy of management's calculations; and
  - evaluating the related disclosures against the requirements of Australian Accounting Standards.
- 

#### **Information other than the financial report and auditor's report thereon**

The Directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2026, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### **Responsibilities of the Directors for the financial report**

The Directors of the Company are responsible for the preparation of:

- a the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 (other than the consolidated entity disclosure statement); and
- b the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: [https://www.auasb.gov.au/media/bwvjcgre/ar1\\_2024.pdf](https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf). This description forms part of our auditor's report.

### Report on the remuneration report

#### Opinion on the remuneration report

We have audited the Remuneration Report included in pages 16 to 30 of the Directors' report for the year ended 30 June 2026.

In our opinion, the Remuneration Report of ClearVue Technologies Limited, for the year ended 30 June 2026 complies with section 300A of the *Corporations Act 2001*.

### Responsibilities

The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Grant Thornton

Grant Thornton Audit Pty Ltd  
Chartered Accountants



B E Burgess  
Partner – Audit & Assurance

Perth, 30 September 2026

## ASX ADDITIONAL INFORMATION

Additional information required by the ASX Limited Listing Rules not disclosed elsewhere in this Annual Report is set out below.

### SHAREHOLDINGS

The issued capital of the Company at 30 September 2026 is 364,005,606 ordinary fully paid shares.

| SHARES RANGE                                             | NO. OF HOLDERS | NO. OF SHARES |
|----------------------------------------------------------|----------------|---------------|
| 1 - 1,000                                                | 384            | 242,231       |
| 1,001 - 5,000                                            | 1,743          | 4,817,255     |
| 5,001 - 10,000                                           | 858            | 6,719,279     |
| 10,001 - 100,000                                         | 1,777          | 66,235,437    |
| Over 100,000                                             | 523            | 285,991,404   |
| 2,526 shareholders holding less than a marketable parcel | 5,285          | 364,005,606   |

| SHAREHOLDERS BY LOCATION | NO. OF HOLDERS | NO. OF SHARES |
|--------------------------|----------------|---------------|
| Australian holders       | 5,201          | 353,403,222   |
| Overseas holders         | 84             | 10,602,384    |
|                          | 5,285          | 364,005,606   |

| TOP 20 SHAREHOLDERS OF QUOTED SHARES AS AT 30 SEPTEMBER 2026 |                                                             |            | NO. OF<br>SHARES<br>HELD | % HELD |
|--------------------------------------------------------------|-------------------------------------------------------------|------------|--------------------------|--------|
| 1                                                            | Luminate Pty Ltd                                            | 20,026,328 |                          | 5.50%  |
| 2                                                            | CITICORP NOMINEES PTY LIMITED                               | 12,674,771 |                          | 3.48%  |
| 3                                                            | Ian Rosenberg                                               | 10,852,772 |                          | 2.98%  |
| 4                                                            | I Rosenberg                                                 | 10,358,057 |                          | 2.85%  |
| 5                                                            | HAWERA PTY LTD <THE BAILEY FAMILY A/C>                      | 8,330,000  |                          | 2.29%  |
| 6                                                            | ELEVATION VENTURES PTY LTD <J3 A/C>                         | 7,050,000  |                          | 1.94%  |
| 7                                                            | Victor Rosenberg                                            | 6,000,000  |                          | 1.65%  |
| 8                                                            | MR CRAIG LEITH DENNIS                                       | 4,750,000  |                          | 1.30%  |
| 9                                                            | AMARILO INVESTMENTS PTY LTD <PJ HUNT SF A/C>                | 4,300,000  |                          | 1.18%  |
| 10                                                           | MRS THERESA ANNE SMITS                                      | 3,225,000  |                          | 0.89%  |
| 11                                                           | RUTHIE PTY LTD <RUTHIE A/C>                                 | 3,000,000  |                          | 0.82%  |
| 12                                                           | BNP PARIBAS NOMINEES PTY LTD <CLEARSTREAM>                  | 2,888,059  |                          | 0.79%  |
| 13                                                           | BNP PARIBAS NOMS PTY LTD                                    | 2,851,661  |                          | 0.78%  |
| 14                                                           | BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>      | 2,808,130  |                          | 0.77%  |
| 15                                                           | RIVERFORT GLOBAL OPPORTUNITIES PCC LTD                      | 2,709,131  |                          | 0.74%  |
| 16                                                           | DAVID & RESMIE GREER PTY LTD <D & R GREER SUPER FUND A/C>   | 2,533,290  |                          | 0.70%  |
| 17                                                           | ELEVATION VENTURES PTY LTD <LYFORD SAMARAS SUPER A/C>       | 2,460,000  |                          | 0.68%  |
| 18                                                           | DR SARJIT JASSAL & MRS HARPAJAN JASSAL                      | 2,371,000  |                          | 0.65%  |
| 19                                                           | SHARESIES AUSTRALIA NOMINEE PTY LIMITED                     | 2,357,095  |                          | 0.65%  |
| 20                                                           | MRS THERESA ANNE SMITS & MR BERT JOSEPH SMITS <SCIS SF A/C> | 2,250,000  |                          | 0.62%  |
|                                                              |                                                             |            | 102,315,078              | 36.72% |

| SUBSTANTIAL SHAREHOLDERS AS AT 30 SEPTEMBER 2026 | NO. OF<br>SHARES HELD | % HELD |
|--------------------------------------------------|-----------------------|--------|
| Luminate Pty Ltd                                 | 20,026,328            | 5.50%  |

### Voting Rights

The holders of ordinary shares are entitled to one vote per share at meetings of the Group.

### OPTION HOLDINGS

| TERMS                                                 | NO. OF OPTIONS    |
|-------------------------------------------------------|-------------------|
| Exercisable at \$0.50 each, expiring 30 November 2026 | 3,000,000         |
| Exercisable at \$0 each, expiring 30 October 2027     | 500,000           |
| Exercisable at \$0.50 each, expiring 13 December 2026 | 2,000,000         |
| Exercisable at \$1.00 each, expiring 13 December 2026 | 2,000,000         |
| Exercisable at \$0.549 each, expiring 30 June 2027    | 1,150,000         |
| Exercisable at \$0.27 each, expiring 20 February 2028 | 989,550           |
| Exercisable at \$0.30 each, expiring 20 February 2029 | 4,000,000         |
|                                                       | <b>13,639,550</b> |

### Unlisted Options (all classes)

| OPTIONS RANGE    | NO. OF HOLDERS | NO. OF SHARES     |
|------------------|----------------|-------------------|
| 1 – 1,000        | -              | -                 |
| 1,001 – 5,000    | -              | -                 |
| 5,001 – 10,000   | -              | -                 |
| 10,001 – 100,000 | 2              | 200,000           |
| 100,001 and over | 21             | 13,439,550        |
|                  | <b>23</b>      | <b>13,639,550</b> |

### Voting Rights

Options have no voting rights.

## PERFORMANCE RIGHTS

| CLASS | TERMS                                                                          | NO. OF PERFORMANCE RIGHTS |
|-------|--------------------------------------------------------------------------------|---------------------------|
| A     | Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s* | 1,000,000                 |
| B     | Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s* | 600,000                   |
| C     | Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s* | 600,000                   |
| D     | Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s* | 700,000                   |
| E     | Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s* | 1,100,000                 |
|       |                                                                                | 4,000,000                 |

The Performance Rights in the relevant class will convert into Shares upon satisfaction of the milestones (see Annual Report for details on milestones)

**Performance Rights (Class A-J)**

| PERFORMANCE RIGHTS RANGE | NO. OF HOLDERS | NO. OF RIGHTS |
|--------------------------|----------------|---------------|
| 1 – 1,000                | –              | –             |
| 1,001 – 5,000            | –              | –             |
| 5,001 – 10,000           | –              | –             |
| 10,001 – 100,000         | –              | –             |
| 100,001 and over         | 3              | 4,000,000     |
|                          | 3              | 4,000,000     |

**Voting Rights**

Performance rights have no voting rights.

### RESTRICTED SECURITIES

There are no restricted securities on issue as at 30 September 2026.

### REQUIREMENT LISTING RULE 4.10.18

In accordance with the listing rule 4.10.18 the Company confirms that it is not currently subject to an on-market buyback.

### CORPORATE GOVERNANCE

The Company's corporate governance statement is found on the Company's website at [Corporate Governance | ClearVue Investor Hub](#)



## HEAD OFFICE & SHOWROOM

📍 Suite 9 / 567 Newcastle Street  
West Perth, Western Australia 6005

☎ +61 8 9220 9020

✉ [hello@clearvuepv.com](mailto:hello@clearvuepv.com)

🌐 [www.clearvuepv.com](http://www.clearvuepv.com)

